

► Additional material is published online only. To view please visit the journal online (http://dx.doi.org/10.1136/ oemed-2015-102879).

¹University Medical Center Hamburg-Eppendorf, Institute for Health Services Research in Dermatology and Nursing, Hamburg, Germany ²Institution for Statutory Accident Insurance and Prevention in Health and Welfare Services, Hamburg, Germany ³Department of Biochemistry, Biophysics and General Pathology, Second University of Naples, Naples, Italy

Correspondence to

Claudia Westermann, University Medical Center Hamburg-Eppendorf, Institute for Health Services Research in Dermatology and Nursing, Martinistrasse 52, Hamburg 20246, Germany; c.westermann@uke.de

Received 10 February 2015 Revised 5 August 2015 Accepted 30 August 2015 Published Online First 5 October 2015





To cite: Westermann C, Peters C, Lisiak B, *et al. Occup Environ Med* 2015;**72**:880–888.

880

Claudia Westermann,¹ Claudia Peters,¹ Birgitte Lisiak,² Monica Lamberti,³ Albert Nienhaus^{1,2}

ABSTRACT

The aim of this study was to estimate the prevalence of viral hepatitis C (HCV) infection among healthcare workers (HCWs) compared to the general population. A systematic search for the years 1989-2014 was conducted in the Medline. Embase and Cochrane databases. Studies on hepatitis C in HCWs were included if they incorporated either a control group or reference data for the general population. The study quality was classified as high, moderate or low. Pooled effect estimates were calculated to determine the odds of occupational infection. Heterogeneity between studies was analysed using the χ^2 test (p < 0.10) and quantified using the I² test. 57 studies met our criteria for inclusion and 44 were included in the meta-analysis. Analysis of high and moderate quality studies showed a significantly increased OR for HCV infection in HCWs relative to control populations, with a value of 1.6 (95% CI 1.03 to 2.42). Stratification by study region gave an OR of 2.1 in low prevalence countries; while stratification by occupational groups gave an increased prevalence for medical (OR 2.2) and for laboratory staff (OR 2.2). The OR for professionals at high risk of blood contact was 2.7. The pooled analysis indicates that the prevalence of infection is significantly higher in HCWs than in the general population. The highest prevalence was observed among medical and laboratory staff. Prospective studies that focus on HCW-specific activity and personal risk factors for HCV infection are needed.

INTRODUCTION

Viral hepatitis C (HCV) infection is caused by blood contact and is a public health problem throughout the world. Its clinical course may be severe and can lead to work disability or to death. Considerable costs are incurred for prophylactic and treatment measures and result from the chronic clinical progress of the disease, loss of working hours and predeath. According to the mature WHO, approximately 150 million people in the world are chronically infected with HCV, and hepatitis C is the cause of 350 000 deaths annually.¹ HCV is mainly transmitted by contact with infected blood due to injuries to the skin or mucous membranes.² Acute infection is often asymptomatic and therefore frequently overlooked. In up to 80% of patients, the clinical course is chronic, leading to an increased risk of developing hepatic cirrhosis or hepatic cell carcinoma.³ Risk factors for HCV infection include intravenous drug consumption, injury-prone sex (men with men) and blood transfusions before the introduction of diagnostic testing. There is no vaccine or postexposure prophylaxis for HCV infection.

Healthcare workers (HCWs) have contact with infected patients and their body fluids. A particularly important factor is repeated performance of exposure prone procedures (EPPs) that may cause injuries to employees.⁴ Injuries to medical and health staff from sharp or pointed objects are among the most frequently reported occupational accidents in healthcare.⁵ The results of epidemiological studies indicate that approximately 80% of HCWs have been affected by needlestick injuries (NSI).⁶ Many such injuries go unreported.⁶⁻⁸ The risk of seroconversion after an injury depends on factors including the type of injury (deep cuts or pricks), the quantity of infectious material transferred, the virus load in the index patient and possibly genetic factors in the injured person.⁸⁻¹⁰

The probability of HCV seroconversion after a NSI in Europe has been estimated as 0.42%.⁶ Although HCV infection as an occupational disease is statistically rare, the consequences for the HCW and the health system are considerable.7 11 12 In 2012, 79 HCV infections were reported to the German Institution for Statutory Accident Insurance and Prevention in Health and Welfare Services, and 47 infections were recognised as occupational diseases.¹³ Numerous studies have investigated the prevalence of HCV in HCWs, but the results have been inconsistent. The objective of the present study is to estimate the prevalence of HCV infection among HCWs compared to the general population. Which professionals are particularly affected by infection?

METHODS

This study is reported in line with the Proposal for Reporting of Meta-analyses of Observational Studies (MOOSE).¹⁴

Search strategy and screening

A systematic literature search was performed in the Medline, Embase and Cochrane databases for the period from 1989 to 2014. This included all prevalence and incidence studies on hepatitis C in HCWs with either a control group or reference data on the general population. The Embase search was performed using the following search terms: ((((('hepatitis C') AND 'occupational exposure') AND 'healthcare worker') AND prevalence) OR incidence)-with and without truncation (see online supplementary file). The search strategy was adapted for the other databases. Additionally, we searched reference lists of the chosen studies and prior reviews. Where it was not possible to make a decision on a study's inclusion or exclusion based on the abstract, the full text of the study was



examined. The studies were screened and their quality was assessed by two reviewers working independently and using predefined checklists. Disagreements were resolved by consensus.

Studies meeting the following criteria were considered for inclusion:

- ▶ Population: HCWs in direct contact with patients or blood
- Exposure: Study examines occupational exposure
- Control: Control group/reference data for general population from other publications
- Outcome: Serological test for HCV
- ▶ Design: Prevalence and incidence studies
- ▶ Languages: German, English, French, Spanish, Portuguese, Italian.

The following criteria led to exclusion from this study:

- ▶ Population: HCWs without direct contact with patients or blood
- ► Exposure: No occupational exposure
- Control: No control group; reference data for the general population not taken from other publications
- Outcome: No serological test for HCV
- ▶ Design: Case reports, surveillance data.

In studies with several control groups, the ones selected were those that best reflected the general population. Studies that examined HCWs without a control group were only included when the results were compared with a population-based study performed within a period of 2 years before or after the actual investigation and in a comparable study region.

In this report, 'healthcare worker' (HCW) is defined as any person (eg, an employee or student) whose activities involve contact with patients or with blood or other body fluids from patients in a healthcare setting.¹⁵

Study quality

In accordance with the literature, we developed an instrument to assess the methodological quality of the observational studies included.^{16–20} Scores were awarded on the basis of the criteria below. A total of nine scores was possible (table 1).

Quality of the laboratory test: Anti-HCV detection depends on the type of test used, and tests differ in quality (product and procedure). In order to standardise the quality assessment, we evaluated the presence of a confirmatory test, but not its quality or procedure. It was not possible to evaluate this in the primary studies, due to missing data.

Statistical analysis

For the meta-analysis, data were extracted from the studies using a standardised documentation form. The parameters were

Item	Criterion	Content	Score
1	Aim	A clearly stated aim	1
2	Sample size	>50 persons	1
3	Response rate	>50%	1
4	Length of employment	Information is available	1
5	Control group	A control group was tested	1
6	Confounder	Adjusted for potential confounders	1
7	Limitations	Were discussed	1
8	Laboratory tests	Performance of anti-HCV test or PCR test	1
		Performance of confirmatory test	1

HCV, viral hepatitis C.

the number of employees examined and the proportion of employees tested as serologically positive. Prevalence ratios (ORs) were calculated as effect estimates using the Mantel-Haenszel method for dichotomous outcomes. The 95% CIs were generated. Additional analyses were performed after stratification by type of controls, study region, publication period, gender and professional group. Meta-analyses were carried out using Review Manager 5.2.

In accordance with the criteria of Trevisan *et al*,⁵⁰ a pooled analysis was performed for professionals exposed to a high risk of blood contact from EPPs. This analysis included the following professions/working areas: surgeons, midwives, microbiologists, pathologists, blood bank and dialysis staff.

Stratification by study region was performed on the basis of national prevalence rates. Based on the publications of Te and Jensen,³ Hahne *et al*²¹ and Mohd Hanafiah *et al*,²² pooled effect estimates were calculated for low prevalence countries taking into account countries of north-west Europe and the USA. Studies from Japan were analysed separately as there have been reports that the rate of seroconversion is higher in Japan than in Europe.⁸

Studies that observed no HCV infection in either group were excluded from the meta-analysis as no information about the relative probability of the event could be derived.¹⁸

Heterogeneity and sensitivity analysis

The presence of heterogeneity was tested using the χ^2 test, taking p<0.10 as the level of significance. An I² test was performed to quantify the diversity between studies. If there was no evidence of heterogeneity, we used a variance approach with a fixed effect model.¹⁸ In cases of statistically significant heterogeneity (χ^2 p value<0.10) and I²>50%, the pooled effect estimate was determined using the random effect model. To identify sources of variation, further stratification was performed relative to study quality and to performance of confirmatory tests. In addition, for the sensitivity analyses, the stability of the pooled estimate with respect to each study was investigated by excluding individual studies from the analysis.

Publication bias

Possible publication bias was visualised with a funnel plot. In addition, the probability of publication bias was tested using Egger's linear regression in SPSS V.20.²³ The level of significance for asymmetry was taken as p<0.1. The calculated intercept is given with a 90% confidence range.

RESULTS

A total of 3016 publications were identified in the databases and 41 by manual search. After checking for duplicates, the titles and abstracts of 954 studies were screened, leading to the exclusion of 801 studies. The full texts of 153 studies were scrutinised and 57 studies were included in the systematic review. This selection process is given in figure 1.

Table 2 gives an overview of the studies included. A total of 27 studies from Europe were included, along with 13 from Asia, eight from Africa, seven from North America and two from South America. In most studies, HCWs were examined within the inter-professional framework. In five studies, the HCWs were stratified by professional group and, in five studies, by working area or exposure. Ten studies examined only a single professional group.

In 33 out of 57 studies, population-based controls, consisting mainly of blood donors, were used. A hospital control group was used in 18 studies. Ciorlia and Zanetta³⁸ used a population-




Figure 1 Selection process. HCWs, health care workers.

based and a hospital control group. Four studies used a population control and several other control groups, including risk groups such as dialysis patients and men who have sex with men.

Study design and quality

Fifty-one studies had a retrospective design and six a prospective design.^{24–29} The annual incidence was reported in two studies only. According to Puro *et al*,²⁴ the rate was 0.1%; and 0.15% according to Cooper *et al*.²⁶

The methodological quality was rated as high in seven studies, as moderate in 33 studies and as poor in 17 studies.

HCV detection

A HCV confirmation test was performed in 37 studies. Five studies used the same test for the confirmation as for the first test. There were differences between the studies with respect to the quality of the tests used (table 2).

HCV exposure among HCWs—a qualitative summary of studies not included in the meta-analysis

Thirteen studies could not be included in the meta-analysis because of missing case numbers (table 2). Increased HCV seroprevalence in HCWs in comparison to population controls was found in four out of seven studies of moderate methodological quality and in three out of six studies of low methodological quality. Cooper *et al*,²⁶ Goetz *et al*⁵³ and Zaaijer *et al*⁶⁶ studied employees stratified by their exposure risk. All seropositive employees worked in areas with high exposure to blood contact (eg, dialysis, blood bank, laboratory), or reported prior NSI.²⁶ With the exception of Mijakoski *et al*,⁷³ all controls were from reference sources.

Meta-analysis

The main results are shown as plots in figure 2. Further results of pooling analyses and subgroup analyses are summarised in online supplementary table S3.

uthor/year	Country	Period	HCV tests	HCWs	n (n+)	Prevalence %	Controls	n (n+)	Prevalence %	Study quality (scores)*
rospective studies										
Puro 1995 ²⁴	Italy	1992–1993	Anti-HCV 2, enzyme immunoassay RIBA 2	S	3073 (67)	2.2	Pr	11 000 (19)	1.7	High (8) ^{1–4 6–8}
Maillard 1996 ²⁵	France	1992–1993	ELISA 2, PCR	S	236 (7)	2.9	Н	305 (2)	0.7	Moderate (6) ^{1 2 5 7}
Coopert1992 ²⁶	USA	NA	EIA RIBA 2	S‡	243 (4)	1.6	Pr	-	0.4–1.4	Moderate (6) ^{1 2 4 7}
Ahmetagic 2006 ²⁷	Bosnia and Herzegovina	2003–2005	ELISA 3, HCV-RNA	S	1699 (6)	0.4	Р	2000 (4)	0.2	Low (4) ^{1 2 5 8}
Daw 2002 ²⁸	Libya	1999–2001	ELISA	S	459 (9)	2	P§	1200 (14)	1.2	Low (4) ^{1 2 5 8}
Mihaly† 2001 ²⁹	Hungary	1986–1998	EIA 2, EIA 3, RIBA 3, PCR	M, NS, CS‡	477 (13)	2.7	Pr	-	0.73–1	Low (4) ^{1 2 8}
etrospective studies	5 7									
Gershon 2007 ³⁰	USA	1999–2000	HCV 2, RIBA 3	S	216 (4)	1.9	Н	94 (3)	3.2	High (9) ^{1–8}
Ozsoy 2003 ³¹	Turkey	1998–2000	Anti-HCV 3 IL, INNOTEST 3, RT-PCR, ELISA	S	702 (2)	0.3	Р	5670 (23)	0.4	High (9) ^{1–8}
Klein 1991 ³²	USA	1985–1987	ELISA 1, RIBA	D	456 (8)	1.8	Р	723 (1)	0.1	High (9) ^{1–8}
Sermoneta-Gertel 2001 ³³	Israel	1995–1997	EIA 3, RIBA 3	S	3657 (34)	0.9	Н	630 (3)	0.5	High (8) ^{1–4} 6–8
Thomas 1996 ³⁴	USA	1991	ELISA 1 or ELISA 2, RIBA	NS	943 (7)	0.7	Р	104,239 (417)	0.4	High (8) ^{1–5} 7 8
Struve 1994 ³⁵	Sweden	NA	EIA 2, Supplementary test	M, NS, L¶	797 (5)	0.6	Н	83 (1)	1.2	High (8) ^{1–5 7 8}
Braczkowska 2006 ³⁶	Poland	2003–2004	ELISA 3,Westem blot LIA HCV Ab3	MS	558 (8)	1.4	Р	510 (2)	0.4	Moderate (7) ^{1–3 5}
Fisker 2004 ³⁷	Denmark	1998	HCV 3, RIBA, PCR	S	960 (2)	0.2	Н	479 (0)	_	Moderate (7) ^{1–5 8}
Ciorlia 2007 ³⁸	Brazil	1994–1999	ELISA 2	S	1433 (25)	1.7	H, P	872 (4) 2583 (6)	1.3 0.2	Moderate (7) ^{1–6 8}
Moens 2000 ³⁹	Belgium	1996–1997	EIA 3, Matrix Abbott und LIA, PCR	S‡	4480 (21)	0.4	Н	426 (0)	_	Moderate (7) ^{1–3} 6
Thorburn 2001 ⁴⁰	Scotland	1994–1996	ELISA 3, PCR, RIBA-3	S, D	10,654 (27)	0.3	Н	471 (3)	0.6	Moderate (7) ^{1–3 5}
Djeriri 1996 ⁴¹	France	1993–1994	EIA 2 RIBA2	S	283 (2)	0.7	Н	93 (0)	-	Moderate (7) ^{1–3 5}
Villate 1993 ⁴²	Spain	1991–1992	ELISA 2, PCR, RIBA 2	M, L, NS¶	874 (14)	1.6	Р	547 (2)	0.4	Moderate (7) ^{1–5 8}
Montella 2005 ⁴³	Italy	1991	ELISA 1, ELISA new generation	M, NS, L¶	578 (32)	5.5	Н	91 (6)	6.6	Moderate (7) ^{1 2 4}
Kaabia 2009 ⁴⁴	Tunisia	2005	ELISA Murex 4, ELISA AxSYM Abbott	M, L, P, Mw¶	737 (9)	1.2	Н	104 (0)	-	Moderate (6) ^{1–3 5}
Irani-Hakime 2001 ⁴⁵	Lebanon	1999	SM-HCV rapid test, MEIA HCV 3, PCR	S	502 (2)	0.4	Р	600 (1)	0.2	Moderate (6) ^{1–3 5}
Campello 1992 ⁴⁶	Italy	1989–1990	ELISA, HCV neutralisation test	S	407 (5)	1.2	Р	253 (2)	0.8	Moderate (6) ^{1 2 4}
Polish 1993 ⁴⁷	USA	1983	Anti-HCV 1 Abbott, HCV neutralisation assay Abbott	S	1350 (22)	1.6	Н	257 (1)	0.4	Moderate (6) ^{1 2 5}
Perez Trallero 1992 ⁴⁸	Spain	NA	ELISA 2, RIBA 2	S	251 (4)	1.6	Р	377 (8)	2.1	Moderate (6) ^{1 2 4}
Takahama 2005 ⁴⁹	Brazil	NA	ELISA 3, PCR, AxSym Abbott 3	D	267 (1)	0.4	Р	88,241 (304)	0.3	Moderate (6) ^{1 2 4}
Trevisan 1999 ⁵⁰	Italy	NA	EIA, RIBA 3	S	809 (9)	1.1	Н	408 (8)	2	Moderate (6) ^{1 2 4}
Webert 2001 ⁵¹	Switzerland	1999	EIA, EIA3, PCR, Immunoblot	D, DS	1056 (1)	0.1	Pr	-	0.5–1	Moderate (6) ^{1 2 4}
Shapiro† 1996 ⁵²	USA	1991	Immunoassay 1, supplementary neutralisation assay	М	3262 (27)	0.8	Pr	-	0.09–0.36	Moderate(6) ^{1 2 4}
Goetz† 1995 ⁵³	USA	NA	EIA 2, RIBA 2, Ortho, PCR	M, D, NS, L‡	241 (5)	1.3	Pr	-	0.3	Moderate (6) ^{1 2 4}
Ahmed 2012 ⁵⁴	Pakistan	2007–2009	ETI-AB-HCV-4	S	41 (7)	17.1	Р	1959 (103)	5.3	Moderate (5) ^{1 4–8}
Fischer 2000 ⁵⁵	USA	1998	PCR	S	502 (0)	_	Н	926 (2)	0.2	Moderate (5) ^{1 2 5}
De Mercato 1996 ⁵⁶	Italy	1995	RIBA 2	S	472 (12)	2.5	Р	285 (8)	2.8	Moderate (5) ^{1 2 4}

Table 2 Continued

Author/year	Country	Period	HCV tests	HCWs	n (n+)	Prevalence %	Controls	n (n+)	Prevalence %	Study quality (scores)*
Olubuyide 1997 ⁵⁷	Nigeria	1995	HCV 3-enzyme Immunoassay Murex	M, D	75 (8)	10.7	Р	25 (3)	12	Moderate (5) ^{1 2 4 7 8}
Al-Sohaibani 1995 ⁵⁸	Saudi Arabia	1992–1994	UBI HCV EIA, RIBA or LiaTEK HCV 3	M, MS¶	330 (8)	2.4	Р	292 (5)	1.7	Moderate (5) ^{1 2 5 8}
Soni 1993 ⁵⁹	South Africa	1991	EIA 2, EIA 2, Abbott neutralisation EIA	NS	212 (0)	-	P§	35 685 (92)	0.3	Moderate (5) ^{1 2 5 8}
Oguchi 1992 ⁶⁰	Japan	1989	ELISA 1 or 2,	S	150 (3)	2	Р	704 (7)	1	Moderate (5) ^{1 2 4 5 8}
Nakashima 1993 ⁶¹	Japan	1987–1988	ELISA, RIBA	S	1097 (11)	1	Р	526 (5)	1	Moderate (5) ^{1 2 5 8}
Fujiyama 1992 ⁶²	Japan	NA	ELISA anti-C100	S	152 (1)	0.7	Р	919 (14)	1.5	Moderate (5) ^{1 2 5 8}
Germanaud** 1994 ⁶³	France	NA	ELISA 2, RIBA 2	S	430 (4)	0.9	Н	180 (3)	1.7	Moderate (5) ^{1 2 5 8}
Jindal† 2006 ⁶⁴	India	2003	Hep-Chex C	S	100 (4)	4	Pr	_	1.6	Moderate (5) ^{1 2–4 8}
Kuot 1993 ⁶⁵	Taiwan	1990–1991	EIA 1, EIA 2, PCR	D	461 (3)	0.7	Pr	_	1	Moderate (5) ^{1 2 4 8}
Zaaijer† 2012 ⁶⁶	The Netherlands	2000–2009	AxSYM HCV, RIBA 3, PCR	S‡	729 (1)	0.1	Pr	_	0.6	Moderate (5) ^{1 2 7 8}
Zuckerman† 1994 ⁶⁷	Scotland	1986, 1991	EIA 2, RIBA 2	S	1053 (3)	0.3	Pr	_	0.3	Low (4) ^{1 2 8}
Jochen** 1992 ⁶⁸	Germany	1992	EIA 2, Immunoblot 2	S	1033 (6)	0.6	Р	2113 (5)	0.2	Low (4) ^{2 5 8}
El Gohary 1995 ⁶⁹	Egypt	1990–1992	EIA 2	S	78 (6)	7.7	Ρ§	271 (39)	14.4	Low (4) ^{1 2 5 8}
Polywka 1991 ⁷⁰	Germany	NA	ELISA	S	217 (6)	2.8	Р	500 (2)	0.4	Low (4) ^{1 2 5 8}
Hindy 1995 ⁷¹	Egypt	NA	ELISA, Abbott, ALT	DS	70 (1)	1.4	Н	35 (6)	17.1	Low (4) ^{1 4 8}
Khan 2011 ⁷²	Pakistan	NA	Immunochromatography test, PCR	S	794 (34)	4.3	Н	30 (0)	-	Low (4) ^{1 2 4 8}
Mijakoski† 2012 ⁷³	Macedonia	NA	anti-HCV Ab	NS	54 (0)	-	Н	32 (0)	-	Low (4) ^{1 4 5 8}
Kondili 2007 ⁷⁴	Albania	NA	EIA 3	S	460 (3)	0.7	Н	22 (0)	-	Low (3) ^{1 5 8}
Libanore** 1992 ⁷⁵	Italy	NA	Immunoassay	S	1008 (41)	4.1	Pr	3572 (34)	1	Low (4) ^{1 2 5 8}
Mujeeb† 1998 ⁷⁶	Pakistan	NA	EIA	S	114 (5)	4.4	Pr	-	0.7	Low (4) ^{1 2 4 8}
Sarkari† 2012 ⁷⁷	Iran	2009–2010	ELISA 3	S	212 (9)	4.2	Pr	-	0.1-0.9	Low (4) ^{1 2 7 8}
Vardas 2002 ⁷⁸	South Africa	1996	ELISA 3, PCR	S	362 (7)	1.9	Н	37 (0)	-	Low (3) ^{1 2 8}
Shoaei† 2012 ⁷⁹	Iran	2010	ELISA	L	203 (0)	-	Pr	-	0.2	Low (3) ^{1 2 8}
De Luca** 1992 ⁸⁰	Italy	1990	NA	S	945 (45)	4.8	P§	3575 (39)	1.1	Low (2) ^{2 5}

() In bold letters: cases confirmed by second test.

*Fulfilled item for quality assessment—see table 1.

†Not included in meta-analysis.

+Stratified by working area/exposure. §Further control groups NA.

¶Stratified by professional groups.

**Editor letter.

CS, cleaning staff; D, medical dental staff; DS, dental staff (Medical and Non-Medical); EIA, enzyme immunoassay; H, hospital controls; HCV, viral hepatitis C; HCWs, healthcare workers; L, laboratory staff; M, medical staff; MS, medical students; Mw, midwives; NA, not available; NS, nursing staff; P, population-based controls; Pr, reference data on population-based controls; RIBA, the recombinant immunoblot assay; S, staff/ HCWs.

A total of 44 studies were included in the pooled analysis (seven high quality studies, 26 moderate quality studies and 11 low quality studies—table 2). The pooled analysis of all studies showed a significantly increased OR of 1.5 (95% CI 1.15 to 2.06) for a HCV infection among HCWs compared to controls, with significant evidence of heterogeneity (χ^2 =110.8, p<0.001,

Study of Subaroup	HCW Events		Con Events		Majaht	Odds Ratio	Odds Ratio M-H, Random, 95% Cl
Study or Subgroup Al-Sohaibani 1995	Events	330	Events 5	292	8.5%	M-H, Random, 95% CI 1.43 [0.46, 4.41]	M-H, Rahdom, 95% Cl
Braczkowska 2006	3	558	2	510	4.4%	1.37 [0.23, 8.25]	
Campello 1992 Ciorlia 2007	5 25	407	2	253 2583	5.1% 11.0%	1.56 [0.30, 8.11] 7.63 [3.12, 18.63]	
Fujiyama 1992	1	152	14	919	3.6%	0.43 [0.06, 3.28]	
Irani-Hakime 2001 Klein 1991	2	502 456	1	600 723	2.7%	2.40 [0.22, 26.50]	
Kieln 1991 Nakashima 1992	11	456	1	526	3.5%	12.89 [1.61, 103.43] 1.06 [0.36, 3.05]	
Ozsoy 2003	2	702	23	5670	6.1%	0.70 [0.17, 2.98]	
Perez Trallero 1992 Puro 1995	4 67	251 3073	8 190	377 11000	7.8%	0.75 [0.22, 2.51] 1.27 [0.96, 1.68]	
Soni 1993	0	212	92	35685	2.1%	0.91 [0.06, 14.63]	
Takahama 2005	1	267	304	88241	3.8%	1.09 [0.15, 7.77]	
Thomas 1996	7	943	417	104239	12.8%	1.86 [0.88, 3.94]	
Total (95% CI)		10383		251618	100.0%	1.58 [1.03, 2.42]	◆
Total events Heterogeneity: Tau ² =	144	- 22 16	1070	/D = 0.04)	- 12 - 4404		
Test for overall effect:	Z = 2.12 (F	= 23.10))	(F = 0.04)	1 = 44.30	5	0.01 0.1 1 10 100 avours [experimental] Favours [control]
							avours (experimental) Travours (control)
Strata: Studies with ser	ological cor	firmator	y tests - p	opulation-	based con	trols	
	HCV	1	Con			Odds Ratio	Odds Ratio
Study or Subgroup	Events	10101	Events		Weight	M-H, Fixed, 95% CI	M-H, Fixed, 95% Cl
Djeriri 1996 Fisker 2004	2	283 960	0	93 479	3.1%	1.66 [0.08, 34.90] 2.50 [0.12, 52.20]	
Germanaud 1994	4	430	3	180	17.5%	0.55 [0.12, 2.50]	
Gershon 2007	4	216	3	94	17.1%	0.57 [0.13, 2.61]	
Klein 1991 Maillard 1996	8 7	456 236	1	723 305	3.2%	12.89 [1.61, 103.43] 4.63 [0.95, 22.50]	
Moens 2000	21	4480	ō	426	3.8%	4.11 [0.25, 68.01]	· · · · · · · · · · · · · · · · · · ·
Polish 1993	22	1350	1	257	6.9%	4.24 [0.57, 31.60]	
Struve 1994 Thomas 1996	5	797 943	1 417	83 104239	7.5%	0.52 [0.06, 4.48] 1.86 [0.88, 3.94]	
Total (95% CI) Total events	82	10151	428	106879	100.0%	2.12 [1.31, 3.42]	•
Heterogeneity: Chi ² =	•2 • 12.19, df =	= 9 (P =	420 0.20); l ² :	= 26%		ţ	
Test for overall effect	Z = 3.06 (P = 0.00	12)				0.01 0.1 1 10 100 vours [experimental] Favours [control]
Strata: Low-HCV preva	alence coun	tries-all	controls				
	HC	w	Co	ntrol		Odds Ratio	Odds Ratio
Study or Subgroup	Events				al Weigh		
Al-Sohaibani 1995	8						
Braczkowska 2006 Campello 1992	3	558					
Klein 1991	8						
Nakashima 1993	2		6			6 1.84 [0.35, 9.63	3]
Ozsoy 2003 Puro 1995	1	219	23				
Takahama 2005	1	261	304				
Villate 1993	4	313	1				
		0.00	1	2 54	7 8.69	6 3.53 (0.64, 19.37	n
Villate 1993 Total (95% CI) Total events		2786	1	2 54 10776		6 3.53 (0.64, 19.37	n
Total (95% CI) Total events Heterogeneity: Chi²	4 34 = 10.05, d	2786 f= 8 (P	363 = 0.26);	2 54 10776	7 8.69	6 3.53 (0.64, 19.37	
Total (95% CI) Total events	4 34 = 10.05, d	2786 f= 8 (P	363 = 0.26);	2 54 10776	7 8.69	6 3.53 (0.64, 19.37	n
Total (95% CI) Total events Heterogeneity: Chi ² Test for overall effec	4 34 = 10.05, d :t: Z = 3.91	2786 f= 8 (P (P < 0.1	363 = 0.26); 0001)	2 54 10776	7 8.69	6 3.53 (0.64, 19.37	
Total (95% CI) Total events Heterogeneity: Chi²	4 34 = 10.05, d :t: Z = 3.91	2786 f= 8 (P (P < 0.1	363 = 0.26); 0001)	2 54 10776	7 8.69	6 3.53 (0.64, 19.37	
Total (95% CI) Total events Heterogeneity: Chi ² Test for overall effec	4 34 = 10.05, d :t: Z = 3.91 population-t	2786 f = 8 (P (P < 0.) based co HCW	363 = 0.26); 0001) ontrols	2 54 10776 3 I ² = 20% Control	7 8.69 2 100.09	6 3.53 (0.64, 19.37 6 2.73 (1.65, 4.51 Odds Ratio	0 0.01 0.1 1 10 100 Favours [hcw] Favours [control]
Total (95% CI) Total events Heterogeneity: Chi [®] Test for overall effec Strata: Medical staff – j Study or Subgroup	4 34 = 10.05, d :t: Z = 3.91 population-t	2786 f = 8 (P (P < 0.1 pased co HCW ents To	363 = 0.26); 0001) ontrols otal Eve	2 54 10776 3 I ² = 20% Control ents To	7 8.69 2 100.09 otal Weig	 3.53 (0.64, 19.37) 2.73 (1.65, 4.51) Odds Ratio M.H. Fixed, 95% 	7 1) 0.01 0.1 1 10 100 Favours [hcw] Favours [control] Odds Ratio CI M-H, Fixed, 95% CI
Total (95% CI) Total events Heterogeneity: Chi ² Test for overall effec Strata: Medical staff – 1 <u>Study or Subgroup</u> Kaabia 2009	4 34 = 10.05, d :t: Z = 3.91 population-t	2786 f = 8 (P (P < 0.) pased co HCW ents To 1	363 = 0.26); 0001) ontrols <u>otal Eve</u> 120	2 54 10776 3 1 ² = 20% Control ents To 0 1	7 8.69 2 100.09 0tal Weig 04 5.3	 3.53 (0.64, 19.37) 2.73 (1.65, 4.51) Odds Ratio ant M-H, Fixed, 95% 2.62 (0.11, 65.0 	0 0.01 0.1 1 10 100 Favours [hcw] Favours [control] 0dds Ratio 0dds Ratio
Total (95% CI) Total events Heterogeneity: Chi ² Test for overall effect Strata: Medical staff – 1 Study or Subgroup Kaabia 2009 Moens 2000 Nakashima 1993	4 34 = 10.05, d :t: Z = 3.91 population-t	2786 f = 8 (P (P < 0.1 based co HCW ents Te 1 1 0	363 = 0.26); 0001) ontrols <u>otal Eve</u> 120 52 45	2 54 10776 3 ² = 20% Control ents Tc 0 1 0 4 5 5	7 8.69 2 100.09 2 100.09 2 100.09 2 100.09 2 100.09 2 100.09 2 100.09 2 100.09 2 100.09	 3.53 [0.64, 19.37 2.73 [1.65, 4.51 Odds Ratio <u>ant M-H, Fixed, 95%</u> 2.62 [0.11, 65.0 2.62 [0.11, 06.71.3] 1.04 [0.06, 19.1] 	1 0 0.01 0.1 1 10 100 Favours [hcw] Favours [control] 0dds Ratio 0dds Ratio 01 01 01 01 01 01 01 01 01 01
Total (95% CI) Total events Heterogeneity: Chi ² Test for overall effec Strata: Medical staff – j Study or Subgroup Kaabia 2009 Moens 2000 Nakashima 1993 Ozsoy 2003	4 34 = 10.05, d :t: Z = 3.91 population-t	2786 f = 8 (P (P < 0.) based co HCW ents To 1 1 0 0	363 = 0.26); 0001) ontrols <u>otal Eve</u> 120 52 45 38	2 54 10776 3 1 ² = 20% Control ents Tc 0 1 0 4 5 5 23 56	7 8.69 2 100.09 2 100.09 04 5.3 26 1.1 126 8.3 170 3.3	 3.53 [0.64, 19.37 2.73 [1.65, 4.51 Odds Ratio ht M-H, Fixed, 95% 2.62 [0.11, 65.0 2.62 [0.11, 65.0 3.42 [0.06, 617.8 3.12 [0.19, 52.3 	r] J] 0.01 0.1 1 10 100 Favours [hcw] Favours [control] CI 0dds Ratio CI M-H, Fixed, 95% CI 19] 7] 4]
Total (95% CI) Total events Heterogeneity: Chi ² Test for overall effect Strata: Medical staff – 1 Study or Subgroup Kaabia 2009 Moens 2000 Nakashima 1993	4 34 = 10.05, d :t: Z = 3.91 population-t	2786 f = 8 (P (P < 0.) based co HCW ents To 1 0 0 2	363 = 0.26); 0001) ontrols <u>otal Eve</u> 120 52 45	2 54 10776 3 1 ² = 20% Control ents Tc 0 1 0 4 5 5 23 56	7 8.69 2 100.09 2 100.09 04 5.3 26 1.1 26 8.3 170 3.3 157 6.1	Odds Ratio M.H., Fixed, 95% 3% 2.6270(1.65, 4.51 M.H., Fixed, 95% 3% 2.627(10, 617 3% 1.04 [0.06, 19.1 3% 4.65 [0.42, 51.8 4.65 [0.42, 51.8]	0 0.01 0.1 10 100 ¹ Favours [hcw] Favours [control] 0.01 0.01 0.01 CI M-H, Fixed, 95% CI 0.01 0.01 0.01 0.01 10 100 Favours [hcw] Favours [hcw] Favours [hcw] 0.01 0.01 0.01 10 10.01 Favours [hcw] Favours [hcw] 0.01 </td
Total (95% CI) Total events Heterogeneity: Chi [®] Test tro verail effect Strata: Medical staff – <u>Study or Subgroup</u> Kaabia 2009 Moens 2000 Notakshima 1993 Ozasy 2003 Polish 1993 Furo 1995 Sermoneta-Gertel 21	4 34 = 10.05, d :t: Z = 3.91 population-t Eve	2786 f = 8 (P (P < 0.) based co HCW nts To 1 1 0 0 2 3 3 2	363 = 0.26); 0001) ontrols 0tal Eve 120 52 45 38 112 378 401	2 54 10776 3 ⁷ = 20% Control ents Tc 0 1 0 4 5 5 23 56 1 2 19 110 3 6	7 8.69 2 100.09 2 100.000 2 100.0000000000000000000000000000000000	0 3.53 (0.64, 19.37 2.73 (1.65, 4.51 0.73 (1.65, 4.51) 0.73 (1.6	0 0.01 0.1 10 100 ¹ Favours [hcw] Favours [control] 0.01 0.01 0.01 0 0.01 0.1 10 100 ¹ Favours [hcw] Favours [control] 0.01 0.01 0 0.01 0.1 10 100 ¹
Total (95% CI) Total events Heterogeneity: Chi ¹⁷ Test for overall effect Strata: Medical staff – j <u>Study or Subgroup</u> Kaabia 2009 Moens 2000 Nakashima 1993 Polish 1993 Pouro 1995 Sermoneta-Gent2 J Struve 1994	4 34 = 10.05, d :t: Z = 3.91 population-t Eve	2786 f = 8 (P (P < 0.) based co HCW ents Te 1 0 0 2 3 3 2 2	363 = 0.26); 0001) ontrols <u>otal Eve</u> 52 45 38 112 378 401 63	2 54 10776 3 1 ² = 20% Control ents Tc 0 1 0 4 5 6 23 56 1 2 19 110 3 6 1	tal Weig 04 5.3 04 5.3 04 5.3 126 1.3 1726 8.3 157 6.6 100 12.4 130 23.3 83 8.4	Odds Ratio Odds Ratio M. H. Fixed, 95% 2.73 [1.65, 4.51 Odds Ratio M. H. H. Fixed, 95% 2.62 (0.11, 650 3.12 (0.11, 650 3.12 (0.11, 651 3.12 (0.11, 651) 4.65 [0.42, 51, 6] 4.65	1) 0.01 0.1 100 Favours [hcw] Favours [control] 0 Odds Ratio CI M-H, Fixed, 95% CI 199 11 177 199 199 100 100 100 100 100 100
Total (95% CI) Total events Heterogeneity: Chi [®] Test for overall effect Strata: Medical staff – j <u>Study or Subgroup</u> Kaabia 2009 Moens 2000 Nakashima 1993 Polish 1993 Polish 1993 Porot 1995 Sermoneta-Genta 2 Struve 1994 Thorburn 2001	4 34 = 10.05, d :t: Z = 3.91 population-t Eve	2786 f = 8 (P (P < 0.) based co HCW ents Te 1 0 0 2 3 3 2 2	363 = 0.26); 0001) ontrols 0tal Eve 120 52 45 38 112 378 401	2 54 10776 3 [≠] = 20% Control ents Tc 0 1 0 4 5 6 23 56 1 2 19 110 3 4 1 3 4	7 8.69 2 100.09 2 100.09 04 5.1 26 1.1 26 1.1 26 8.3 70 3.1 57 6.0 00 12.4 30 23.1 83 8.4 71 31.1	0 3.53 (0.64, 19.37) 2.73 (1.65, 4.51) 2.73 (1.65, 4.51) 0 0.0dds Ratio pt M.H., Fixed, 95% 2.62 (0.11, 65) 3.22 (0.11, 65) 3.22 (0.11, 65) 3.23 (0.10, 617) 3.12 (0.10, 157) 3.12 (0.11, 95, 23) 3.465 (0.42, 513, 656) 4.62 (1.36, 156) 3.53 (0.64, 10.617) 3.12 (0.12, 93, 156) 3.53 (0.64, 10.617) 3.12 (0.12, 93, 156) 3.53 (0.64, 10.617) 3.53 (0.64, 10.617) 3.53 (0.64, 10.617) 3.53 (0.64, 10.617) 3.53 (0.64, 10.617) 3.53 (0.64, 10.617) 3.53 (0.64, 10.617) 3.53 (0.64, 10.617) 3.53 (0.64, 10.617) 3.53 (0.64, 10.617) 3.53 (0.64, 10.617) 3.53 (0.64, 10.617) 3.53 (0.64, 10.617) 3.53 (0.64, 10.617) 3.53 (0.64, 10.617) 3.53 (0.64, 10.617) 3.53 (0.64, 10.617) 3.53 (0.64, 10.617) 3.53 (0.64, 10.617) 3.53 (0.61, 10.617)	1) 0.01 0.1 100 Favours [hcw] Favours [control] 0 Odds Ratio CI M-H, Fixed, 95% CI 199 11 177 199 199 100 100 100 100 100 100
Total (95% C)) Total events Heterogeneth; Chi [*] Test for overall effect Strata: Medical staff – 1 <u>Study or Subgroup</u> Kaabia 2009 Moens 2000 Nakashima 1993 Ozay 2003 Polish 1993 Puro 1995 Sermoneta-Gettel 20 Struet 1994 Thorburn 2001 Total (95% C)	4 34 = 10.05, d :t: Z = 3.91 population-t Eve	2786 f = 8 (P (P < 0.) based co HCW ents To 1 0 0 2 3 3 2 3 3 3 1	363 = 0.26); 0001) ontrols <u>otal Eve</u> 52 45 38 112 378 401 63	2 54 10776 3 I ^P = 20% Control ents Tc 0 1 0 4 5 5 23 56 1 2 19 110 3 4 191	tal Weig 04 5.3 04 5.3 05 6.6 126 1.7 126 1.7 157 6.6 100 12.8 130 23.3	0 3.53 (0.64, 19.37) 2.73 (1.65, 4.51) 2.73 (1.65, 4.51) 0 0.0dds Ratio pt M.H., Fixed, 95% 2.62 (0.11, 65) 3.22 (0.11, 65) 3.22 (0.11, 65) 3.23 (0.10, 617) 3.12 (0.10, 157) 3.12 (0.11, 95, 23) 3.465 (0.42, 513, 656) 4.62 (1.36, 156) 3.53 (0.64, 10.617) 3.12 (0.12, 93, 156) 3.53 (0.64, 10.617) 3.12 (0.12, 93, 156) 3.53 (0.64, 10.617) 3.53 (0.64, 10.617) 3.53 (0.64, 10.617) 3.53 (0.64, 10.617) 3.53 (0.64, 10.617) 3.53 (0.64, 10.617) 3.53 (0.64, 10.617) 3.53 (0.64, 10.617) 3.53 (0.64, 10.617) 3.53 (0.64, 10.617) 3.53 (0.64, 10.617) 3.53 (0.64, 10.617) 3.53 (0.64, 10.617) 3.53 (0.64, 10.617) 3.53 (0.64, 10.617) 3.53 (0.64, 10.617) 3.53 (0.64, 10.617) 3.53 (0.64, 10.617) 3.53 (0.64, 10.617) 3.53 (0.61, 10.617)	1) 0.01 0.1 100 Favours (hcw) Favours (control) 00dds Ratio 01 01 01 01 01 01 01 01 01 01
Total (95% CI) Total events Heterogeneity: Chi [®] Test for overall effect Strata: Medical staff – j <u>Study or Subgroup</u> Kaabia 2009 Molens 2000 Nakashima 1993 Polish 1993 Polish 1993 Pouro 1995 Sermoneta-Gertel 21 Struve 1994 Thorbum 2001 Total (95% CI) Total events	4 34 = 10.05, d :t: Z = 3.91 population-t Eve	2786 f= 8 (P (P < 0.) based oc HCW HCW 1 1 1 1 1 1 2 2 3 2 2 3 2 3 1 1 1 1	363 = 0.26); 0001) ontrols 0001 52 45 38 112 378 401 63 533 742	2 54 10776 3 P= 20% Control ents Tc 0 1 0 4 5 5 1 2 19 110 3 4 191 55	7 8.69 2 100.09 2 100.09 04 5.1 26 1.1 26 1.1 26 8.3 70 3.1 57 6.0 00 12.4 30 23.1 83 8.4 71 31.1	0 3.53 (0.64, 19.37) 2.73 (1.65, 4.51) 2.73 (1.65, 4.51) 0 0.0dds Ratio pt M.H., Fixed, 95% 2.62 (0.11, 6.6) 24.84 (1.00, 617, 8) 3.12 (0.10, 157, 3) 3.12 (0.11, 52, 3) 3.46 (5) (4.2, 51, 36, 156, 10, 617, 8) 3.12 (0.12, 52, 3) 4.65 (0.4, 2, 51, 36, 156, 10, 617, 8) 2.68 (0.24, 30, 3) 3.53 (0.64, 10, 617, 8) 2.68 (0.24, 30, 3) 3.53 (0.64, 10, 617, 8) 2.68 (0.12, 8), 44 3.53 (0.64, 10, 617, 8) 3.68 (0.18, 4.4)	0 0.01 0.1 10 100 Favours [hcw] Favours [control] 00
Total (95% C)) Total events Heterogeneth; Chi [*] Test for overall effect Strata: Medical staff – 1 <u>Study or Subgroup</u> Kaabia 2009 Moens 2000 Nakashima 1993 Ozay 2003 Polish 1993 Puro 1995 Sermoneta-Gettel 20 Struet 1994 Thorburn 2001 Total (95% C)	4 34 = 10.05, d :t: Z = 3.91 population-t Eve 001 = 6.23, df=	2786 f = 8 (P < 0.) based oc HCW ents Tri 0 0 2 2 3 3 2 3 4 2 3 4 11 1 4 8 (P =	363 = 0.26); 0001) ontrols <u>otal Eve</u> 52 45 38 112 378 401 63 533 7742 0.62); I [#] =	2 54 10776 3 P= 20% Control ents Tc 0 1 0 4 5 5 1 2 19 110 3 4 191 55	7 8.69 2 100.09 2 100.09 04 5.1 26 1.1 26 1.1 26 8.3 70 3.1 57 6.0 00 12.4 30 23.1 83 8.4 71 31.1	0 3.53 (0.64, 19.37) 2.73 (1.65, 4.51) 2.73 (1.65, 4.51) 0 0.0dds Ratio pt M.H., Fixed, 95% 2.62 (0.11, 6.6) 24.84 (1.00, 617, 8) 3.12 (0.10, 157, 3) 3.12 (0.11, 52, 3) 3.46 (5) (4.2, 51, 36, 156, 10, 617, 8) 3.12 (0.12, 52, 3) 4.65 (0.4, 2, 51, 36, 156, 10, 617, 8) 2.68 (0.24, 30, 3) 3.53 (0.64, 10, 617, 8) 2.68 (0.24, 30, 3) 3.53 (0.64, 10, 617, 8) 2.68 (0.12, 8), 44 3.53 (0.64, 10, 617, 8) 3.68 (0.18, 4.4)	DODD Favours [control]
Total (95% CI) Total events Heterogeneth; Chi [*] Test for overall effect Strata: Medical staff – 1 <u>Study or Subgroup</u> (Kaabia 2009 Moens 2000 Nakashima 1993 Ozay 2003 Polish 1993 Puro 1995 Serroneta-Gettel 2 Struet 1994 Thorburn 2001 Total (95% CI) Total events Heterogeneth; Chi [*]	4 34 = 10.05, d :t: Z = 3.91 population-t Eve 001 = 6.23, df=	2786 f = 8 (P < 0.) based oc HCW ents Tri 0 0 2 2 3 3 2 3 4 2 3 4 11 1 4 8 (P =	363 = 0.26); 0001) ontrols <u>otal Eve</u> 52 45 38 112 378 401 63 533 7742 0.62); I [#] =	2 54 10776 3 P= 20% Control ents Tc 0 1 0 4 5 5 1 2 19 110 3 4 191 55	7 8.69 2 100.09 2 100.09 04 5.1 26 1.1 26 1.1 26 8.3 70 3.1 57 6.0 00 12.4 30 23.1 83 8.4 71 31.1	0 3.53 (0.64, 19.37) 2.73 (1.65, 4.51) 2.73 (1.65, 4.51) 0 0.0dds Ratio pt M.H., Fixed, 95% 2.62 (0.11, 6.6) 24.84 (1.00, 617, 8) 3.12 (0.10, 157, 3) 3.12 (0.11, 52, 3) 3.46 (5) (4.2, 51, 36, 156, 10, 617, 8) 3.12 (0.12, 52, 3) 4.65 (0.4, 2, 51, 36, 156, 10, 617, 8) 2.68 (0.24, 30, 3) 3.53 (0.64, 10, 617, 8) 2.68 (0.24, 30, 3) 3.53 (0.64, 10, 617, 8) 2.68 (0.12, 8), 44 3.53 (0.64, 10, 617, 8) 3.68 (0.18, 4.4)	0 0.01 0.1 10 100 Favours [hcw] Favours [control] 00
Total (95% CI) Total events Heterogeneth; Chi [*] Test for overall effect Strata: Medical staff – 1 <u>Study or Subgroup</u> (Kaabia 2009 Moens 2000 Nakashima 1993 Ozay 2003 Polish 1993 Puro 1995 Serroneta-Gettel 2 Struet 1994 Thorburn 2001 Total (95% CI) Total events Heterogeneth; Chi [*]	4 34 = 10.05, d t: Z = 3.91 population-t Eve 001 = 6.23, df = t Z = 2.24	2786 f=8 (P < 0.) HCW ents 1 0 0 2 3 3 1 1 2 4 2 3 4 1 1 4 8 (P = 0.)	363 = 0.26); 0001) ontrols <u>otal Eve</u> 52 45 38 112 378 401 63 533 7742 0.62); I [#] =	2 54 10776 3 P= 20% Control ents Tc 0 1 0 4 5 5 1 2 19 110 3 4 191 55	7 8.69 2 100.09 2 100.09 04 5.1 26 1.1 26 1.1 26 8.3 70 3.1 57 6.0 00 12.4 30 23.1 83 8.4 71 31.1	0 3.53 (0.64, 19.37) 2.73 (1.65, 4.51) 2.73 (1.65, 4.51) 0 0.0dds Ratio pt M.H., Fixed, 95% 2.62 (0.11, 6.6) 24.84 (1.00, 617, 8) 3.12 (0.10, 157, 3) 3.12 (0.11, 52, 3) 3.46 (5) (4.2, 51, 36, 156, 10, 617, 8) 3.12 (0.12, 52, 3) 4.65 (0.4, 2, 51, 36, 156, 10, 617, 8) 2.68 (0.24, 30, 3) 3.53 (0.64, 10, 617, 8) 2.68 (0.24, 30, 3) 3.53 (0.64, 10, 617, 8) 2.68 (0.12, 8), 44 3.53 (0.64, 10, 617, 8) 3.68 (0.18, 4.4)	DODD Favours [control]
Total (95% CI) Total events Heterogeneity: Chi [®] Test for overall effect Strata: Medical staff – j <u>Study or Subgroup</u> Kaabia 2009 Moens 2000 Nakashima 1993 Polish 1993 Polish 1993 Polish 1993 Polish 1993 Sermoneta-Genel 2 Struve 1994 Thorburn 2001 Total (95% CI) Total events Heterogeneity: Chi [®] .	4 34 = 10.05, di :t: Z = 3.91 population-t Eve 001 = 6.23, df = t: Z = 2.24 7-all controls	2786 f= 8 (P < 0.) based co HCW ents Tr 1 0 0 2 3 3 2 2 3 2 3 2 3 2 1 1 1 4 8 (P = 0.0	36: = 0.26); 0001) ontrols 001 Eve 120 52 45 38 112 378 401 63 533 742 0.62); F:	2 54 10776 3 1 ^P = 20% Control ents Tc 0 1 1 2 19 11C 3 2 1 2 19 11C 3 4 1 3 4 1 55 50%	7 8.69 2 100.09 2 100.09 04 5.1 26 1.1 26 1.1 26 8.3 70 3.1 57 6.0 00 12.4 30 23.1 83 8.4 71 31.1	Odds Ratio 0.4 2.53 (0.64, 19.37 2.73 [1.65, 4.51 2.73 [1.65, 4.51 0.1 M.H., Fixed, 95% 0.2 2.62 (0.11, 65.0) 1.04 (0.06, 18.1) 1.04 (0.06, 18.1) 1.04 (0.06, 18.1) 1.04 (0.06, 18.1) 3.63 (0.42, 71.8) 1.05 (0.17, 6.3) 4.65 (0.42, 71.8) 1.05 (0.17, 6.3) 5.68 (0.18, 16.10, 17.8) 0.88 (0.18, 4.4) 0.9% 2.20 (1.10, 4.3)	n n n n n n n n n n n n n n
Total (95% C) Total events Heterogeneth; Chi [*] Test for overall effect Strata: Medical staff – J Study or Subgroup Kaabia 2009 Moens 2000 Nakashima 1993 Ozavy 2003 Polish 1993 Puro 1995 Sermoneta-Gentel 20 Struet 1994 Total (95% C) Total (95% C) Total events Heterogeneth; Chi [*] Test for overall effect Strata: Laboratory staff	4 344 = 10.05, d :t: Z = 3.91 population-t Eve 001 = 6.23, df = t: Z = 2.24 f-all controls	2786 f= 8 (P < 0.) (P < 0.) based oc HCW ents Tri 1 0 0 2 2 3 3 2 4 2 3 3 4 11 1 8 (P = 0.0 3 3 4 8 (P = 0.0 3 4 11 1 1 8 (P = 0.0 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	366;2 = 0.26); 00001) ontrols <u>otal Eve</u> 52 45 53 38 112 533 7742 0.62); F [±] ; 0.62); F [±] ;	2 54 10776 3 1076 2 2 2 2 2 5 5 1 1 3 4 19 10 3 4 5 5 5 5 5 5 5 5 5 5 5 5 5	tal Weig 2 100.0 ⁴ 2 100.0 ⁴ 5. 26 1. 26 1. 26 8. 5. 5. 7 8. 5. 8. 8. 9. 100.0 ⁴ 5. 5. 5. 6. 8. 8. 9. 9. 9. 9. 9. 9. 9. 9. 9. 9	 3.53 (0.84, 19.37) 2.73 [1.65, 4.51 2.73 [1.65, 4.51 2.73 [1.65, 4.51 2.62 [0.11, 0.50] 2.62 [0.11, 0.50] 2.62 [0.11, 0.50] 3.64 [0.00, 613] 4.65 [0.44, 514] 3.64 [0.00, 613] 4.65 [0.44, 514] 3.64 [0.14, 514] 4.65 [0.14, 514]<!--</td--><td>0 0 0 0 0 0 0 0 0 0 0 0 0 0</td>	0 0 0 0 0 0 0 0 0 0 0 0 0 0
Total (95% CI) Total events Heterogeneity: Chi [®] Test for overall effect Strata: Medical staff – j <u>Study or Subgroup</u> Kaabia 2009 Moens 2000 Nakashima 1993 Polish 1993 Polish 1993 Polish 1993 Polish 1993 Sermoneta-Genel 2 Struve 1994 Thorburn 2001 Total (95% CI) Total events Heterogeneity: Chi [®] .	4 344 = 10.05, d :t: Z = 3.91 population-t Eve 001 = 6.23, df = t: Z = 2.24 f-all controls	2786 f= 8 (P < 0.) vased cc HCW ents Tr 1 0 0 2 3 3 4 1 1 8 (P = 0.0 5 HCW nts Tc	36: = 0.26); 0001) ontrols 001 Eve 120 52 45 38 112 378 401 63 533 742 0.62); F:	2 54 10776 3 1 ^P = 20% Control 1 ^P = 20% Control 19 110 1 2 19 110 1 2 19 110 1 2 19 10 55 = 0% Control Control 10 2 10 2	7 8.69 2 100.09 2 100.09 04 5.1 26 1.1 26 1.1 26 8.3 70 3.1 57 6.0 00 12.4 30 23.1 83 8.4 71 31.1	Odds Ratio 0 3.53 (0.64, 19.37 % 2.73 (1.65, 4.51 0 0.43 Ratio 0 1.04 (0.61, 8.17) 1 0.40 (0.61, 8.17) 1 1.04 (0.61, 8.17) 3 1.04 (0.61, 8.17) 3 4.65 (0.42, 51.8) 5% 4.65 (0.42, 51.8) 1.05 (0.61, 7.8) 1.05 (0.17, 8.3) 3% 0.88 (0.18, 4.4) 0% 2.20 (1.10, 4.3) Odds Ratio 0.44 (0.43, 95%)	Dot 0.1 100 Favours [hcw] Favours [control]
Total (95% CI) Total events Heterogeneth; Chi ² Test for overall effect Strata: Medical staff – j Study or Subgroup Kaabia 2009 Natashima 1993 Ozaby 2003 Polish 1993 Polish 1993 Polish 1993 Stermoneta-Gentel 21 Strata: Laboratory staf Strata: Laboratory staf Strata: Laboratory staf	4 344 344 344 340 34 34 34 34 34 34 34 34 34 34 34 34 34	2786 f=8 (P (P < 0.)	366; 9.26); ; 00001) ontrols otal Eve 45 38 112 63 38 112 63 533 742 0.62); P-: 533 742 0.62); P-: 533 ((0.62); P-: 533 742 0.62); P-: 553 742 0.62); P-: 557 742 0.62); P-: 557 553 742 0.62); P-: 557 553 742 0.557 557 553 553 553 553 553 557 557	2 54 10776 3 Control ents Tc 5 5 1 2 3 4 5 5 5 5 5 5 5 5 5 5 5 5 5	tal Weight 04 5.3. 05 6.6. 07 8.69 100.01 6.1. 03 5.7. 100 1.3. 100 1.3. 101 1.3. 102 1.1. 103 2.3. 104 1.3. 105 1.0. 106 1.3. 107 1.3. 108 1.3. 109 1.3. 100 1.3. 101 1.3. 102 2.3. 103 3.3.	0 3.53 (0.64, 19.37) 2.73 [1.65, 4.51] 0.0dds Ratio 0 M.H., Fixed, 95% 2.82 (0.11, 65.0) 24.84 (1.00, 617.8) 3.12 (0.12, 33.12) 3.12 (0.12, 33.12) 3.46 (0.12, 33.12) 3.46 (0.12, 33.12) 4.62 (1.36, 15.6) 2.68 (0.12, 43.3) 7% 0.88 (0.18, 4.4) 0.9% 2.20 (1.10, 4.3) 4.62 (1.36, 15.6) 3.13 (0.14, 14.12) 1.34 (0.14, 14.12) 1.34 (0.14, 14.12)	1 0 0 0 0 0 0 0 0 0 0 0 0 0
Total (95% CI) Total events Heterogeneth; Chi [#] Test for overall effect Strata: Medical staff – 1 Study or Subgroup Kaabia 2009 Moens 2000 Nakashima 1993 Ozay 2003 Polish 1993 Puro 1995 Sermoneta-Gettel 2 Struet 1994 Total (95% CI) Total events Heterogeneth; Chi [®] Test for overall effect Strata: Laboratory staff	4 344 344 344 340 34 34 34 34 34 34 34 34 34 34 34 34 34	2786 f=8 (P (P < 0.)	366; 9.26); (0001) ontrols otal Eve 45 38 112 63 38 116 63 533 742 0.62); (° : 533 742 0.62); (° : 545 742 0.62); (° : 553 742 0.62); (° : 557 553 754 553 754 553 754 553 754 553 754 553 754 553 754 557 755 757 757 757 757 757	2 54 10776 3 1 ^P = 20% Control 1 0 4 5 6 2 3 56 1 1 3 4 19 110 3 4 19 110 5 5 = 0% Control 1 7 1 7 1 7	tal Weight 04 5.3. 05 6.6. 07 8.69 100.01 6.1. 03 5.7. 100 1.3. 100 1.3. 101 1.3. 102 1.1. 103 2.3. 104 1.3. 105 1.0. 106 1.3. 107 1.3. 108 1.3. 109 1.3. 100 1.3. 101 1.3. 102 2.3. 103 3.3.	0 3.53 (0.64, 19.37) 2.73 [1.65, 4.51] 0.0dds Ratio 0 M.H., Fixed, 95% 2.82 (0.11, 65.0) 24.84 (1.00, 617.8) 3.12 (0.12, 33.12) 3.12 (0.12, 33.12) 3.46 (0.12, 33.12) 3.46 (0.12, 33.12) 4.62 (1.36, 15.6) 2.68 (0.12, 43.3) 7% 0.88 (0.18, 4.4) 0.9% 2.20 (1.10, 4.3) 4.62 (1.36, 15.6) 3.13 (0.14, 14.12) 1.34 (0.14, 14.12) 1.34 (0.14, 14.12)	1 0 0 0 0 0 0 0 0 0 0 0 0 0
Total (95% CI) Total events Heterogeneth; Chi ² Test for overall effect Strata: Medical staff – j Study or Subgroup Kaabia 2009 Natashima 1993 Ozaby 2003 Polish 1993 Polish 1993 Polish 1993 Stermoneta-Gentel 21 Strata: Laboratory staf Strata: Laboratory staf Strata: Laboratory staf	4 344 344 344 340 34 34 34 34 34 34 34 34 34 34 34 34 34	2786 f= 8 (P < 0.)	366; 9.26); ; 00001) ontrols otal Eve 45 38 112 63 38 112 63 533 742 0.62); P-: 533 742 0.62); P-: 533 ((0.62); P-: 533 742 0.62); P-: 553 742 0.62); P-: 557 742 0.62); P-: 557 553 742 0.62); P-: 557 553 742 0.557 557 553 553 553 553 553 557 557	2 54 10776 3 Control ents Tc 0 1 5 5 5 23 5 4 1 2 1 2 1 3 1 2 1 3 1 2 1 3 1 2 5 9 1 2 5 9 1 2 5 9 1 2 5 9 1 2 5 9 1 2 5 9 1 2 5 9 5 9 5 9 5 9 5 9 5 9 5 9 5 9	tal Weight 04 5.3. 05 6.6. 07 8.69 08 5.3. 09 7.0. 100 1.3. 100 1.3. 101 1.3. 101 1.3. 102 1.1. 103 2.3. 104 1.3. 105 1.3. 107 1.3. 108 1.3. 109 1.3. 100 1.3. 101 1.3. 102 2.3. 103 3.3.	0dds Ratio MH, Fixed, 95% 2.23 [1.65, 4.51 0dds Ratio hMH, Fixed, 95% 2.63 [0.10, 617 32 2.62 [0.11, 650, 10.617 33 12 [0.10, 617 34 2.64 [1.00, 617 35 2.62 [0.11, 650, 10.617 36 2.63 [0.11, 650, 10.617 36 4.62 [1.36, 156 37 (0.10, 617 38 (0.18, 4.4 0.88 [0.18, 4.4 0% 2.20 [1.10, 4.3 0% 2.20 [1.10, 4.3 0% 2.20 [1.10, 4.3 1.34 [0.14, 12.9] 1.34 [0.14, 12.9] 3.13 [0.14, 12.9] 3.13 [0.14, 12.9] 1.09 [0.15, 7.7] 1.09 [0.15, 7.7]	D Odds Ratio CI M-H, Fixed, 95% CI 00 00 00 00 00 00 00 00 00 0
Total (95% CI) Total avents Heterogeneh; Chi ² Test for overall effect Strata: Medical staff – j Study or Subgroup Kaabia 2009 Makashima 1993 Ozaby 2003 Polish 1993 Polish 1993 Polish 1993 Sermoneta-Gentel 2; Strue 1994 Thorbum 2001 Total (95% CI) Total events Strata: Laboratory staff Strata: Laboratory staff	4 33, 34 34, 35, 36, 36, 36, 36, 36, 36, 36, 36, 36, 36	2786 f=8 (P < 0.)	363 = 0.26); 00001) ontrois 0001 Eve 52 52 52 53 38 38 38 38 38 378 401 63 533 378 401 63 533 378 401 63 533 3742 0.62); F* 57 57 57 57 57 57 57 57 57 57 57 57 57	2 54 10776 3 Control 10 4 5 5 10 4 5 5 10 4 19 110 3 4 19 110 5 5 10 4 10 4 10 4 5 5 10 4 10 10 10 3 10 3 10 4 10 10 10 3 10 3	tal Weight 04 5.5. 100.0° 5.7. 0.4 5.7. 1.70 3.1. 3.83 8.8. 7.1 3.1.3. 1.67 100. tal Weight wave 3.1.3. 1.33 3.3.5. 1.4 48.4	0dds Ratio MH, Fixed, 95% 2.23 [1.65, 4.51 0dds Ratio hMH, Fixed, 95% 2.63 [0.10, 617 32 2.62 [0.11, 650, 10.617 33 12 [0.10, 617 34 2.64 [1.00, 617 35 2.62 [0.11, 650, 10.617 36 2.63 [0.11, 650, 10.617 36 4.62 [1.36, 156 37 (0.10, 617 38 (0.18, 4.4 0.88 [0.18, 4.4 0% 2.20 [1.10, 4.3 0% 2.20 [1.10, 4.3 0% 2.20 [1.10, 4.3 1.34 [0.14, 12.9] 1.34 [0.14, 12.9] 3.13 [0.14, 12.9] 3.13 [0.14, 12.9] 1.09 [0.15, 7.7] 1.09 [0.15, 7.7]	D Odds Ratio CI M-H, Fixed, 95% CI 00 00 00 00 00 00 00 00 00 0
Total (95% C) Total events Heterogeneth; Chi [*] Test for overall effect Strata: Medical staff – 1 Study or Subgroup Kaabia 2009 Moens 2000 Nakashima 1993 Ozavy 2003 Polish 1993 Ozavy 2003 Polish 1993 Strue 1994 Strue 1994 Total (95% C) Total (95% C) Total (95% C) Total (95% C) Strata: Laboratory staff Settory or Subgroup Kellerogeneth; Chi [*] Test for overall effect Strata: Laboratory staff Settory or Subgroup Total (95% C) Total (95% C)	4 34,4 34,4 34,4 34,4 34,4 34,4 34,4 34	2786 f=8 (P < 0.) based cc HCW HCW 1 1 1 0 0 2 2 4 3 3 11 1 4 2 2 3 3 11 1 4 8 (P = 0.0 8 HCW HCW 1 1 1 2 2 4 1 1 1 2 2 2 1 1 1 2 2 2 2	368: 308: 309: 300001) ontrols 52 52 52 52 53 378 45 53 378 45 53 378 45 53 378 45 53 742 0.62); P: 57 57 57 57 57 57 58 53 53 53 53 53 53 53 53 53 53	2 54 10776 3 Control 10 4 5 5 10 4 5 5 10 4 19 110 3 4 19 110 5 5 10 4 10 4 10 4 5 5 10 4 10 10 10 3 10 3 10 4 10 10 10 3 10 3	tal Weight 04 5.5. 100.0° 5.7. 0.4 5.7. 1.70 3.1. 3.83 8.8. 7.1 3.1.3. 1.67 100. tal Weight wave 3.1.3. 1.33 3.3.5. 1.4 48.4	0 3.53 (0.84, 19.37) 5 2.73 (1.65, 4.51) 0 0.04ds Ratio pt M.H., Fixed, 95%, 93% 2.82 (0.11, 65) 3.22 (0.11, 65) 3.12 (0.10, 617 3.12 (0.11, 23) 3.13 (0.11, 23, 156) 3.12 (0.11, 23) 3.48 (0.12, 13), 156 3.23 (0.11, 24) 3.53 (0.11, 24) 0.68 (0.12, 13) 4.68 (0.42, 518) 0.88 (0.12, 43) 0.58 (0.12, 44) 0% 2.20 (1.10, 4.3) 0.54 (1.37, 9.15) 1.10 (0.15, 7.7) % 3.54 (1.37, 9.15) 1.38 (1.37, 9.15)	Dot 0.1 1 10 100 Favours [hcw] Favours [control] 00dds Ratio CI M-H, Fixed, 95% CI 10 00 10 10 10 10 10 10 10 10
Total (95% C)) Total events Heterogeneth; Chi [#] Test for overall effect Strata: Medical staff – 1 Study or Subgroup Kaabia 2009 Moens 2000 Nakashima 1993 Ozavy 2003 Polish 1993 David 1995 Sermoneta-Gentel 2 Struet 1994 Total (95% C)) Total (95% C) Total (95% C) Stata: Laboratory staff Settay or Subgroup Kelerogeneth; Chi [#] Test for overall effect Strata: Laboratory staff Settay or Subgroup Total (95% C)) Total events Heterogeneth; Chi [#] Test for overall effect Total (95% C)) Total events Heterogeneth; Chi [#] Setta: Laboratory staff Setta: Laboratory	4 344 344 344 344 344 344 344 344 344 3	2736 f = 8 (P < 0.) based oc HCW ents Tr 1 0 0 2 2 3 4 1 1 1 0 0 2 2 3 4 1 1 1 1 1 1 1 1 1 1 1 1 1	3663 52 52 52 52 52 52 52 52 52 53 742 0.62); F= 53 742 0.62); F= 57 57 57 57 57 57 57 57 57 57	2 54 10776 3 3 7 0 1 0 1 23 56 23 51 23 56 1 2 1 2 55 55 = 0% 1 56 7 34 895 304 892 895 3008 44% 14%	tal Weight 04 5.5. 100.0° 5.7. 0.4 5.7. 1.70 3.1. 3.83 8.8. 7.1 3.1.3. 1.67 100. tal Weight wave 3.1.3. 1.33 3.3.5. 1.4 48.4	0 3.53 (0.84, 19.37) 5 2.73 (1.65, 4.51) 0 0.04ds Ratio pt M.H., Fixed, 95%, 93% 2.82 (0.11, 65) 3.22 (0.11, 65) 3.12 (0.10, 617 3.12 (0.11, 23) 3.13 (0.11, 23, 156) 3.12 (0.11, 23) 3.48 (0.12, 13), 156 3.23 (0.11, 24) 3.53 (0.11, 24) 0.68 (0.12, 13) 4.68 (0.42, 518) 0.88 (0.12, 43) 0.58 (0.12, 44) 0% 2.20 (1.10, 4.3) 0.54 (1.37, 9.15) 1.10 (0.15, 7.7) % 3.54 (1.37, 9.15) 1.38 (1.37, 9.15)	0 0.01 0.1 10 100 Favours [hcw] Favours [control] 0.01 0.01 0.01 0 0.01 0.1 10 100 100 10 M-H, Fixed, 95% CI 99% 0.01
Total (95% C) Total events Heterogeneth; Chi [*] Test for overall effect Strata: Medical staff – 1 Study or Subgroup Kaabia 2009 Moens 2000 Nakashima 1993 Ozavy 2003 Polish 1993 Ozavy 2003 Polish 1993 Strue 1994 Strue 1994 Total (95% C) Total (95% C) Total (95% C) Total (95% C) Strata: Laboratory staff Settory or Subgroup Kellerogeneth; Chi [*] Test for overall effect Strata: Laboratory staff Settory or Subgroup Total (95% C) Total (95% C)	4 344 344 344 344 344 344 344 344 344 3	2736 f = 8 (P < 0.) based oc HCW ents Tr 1 0 0 2 2 3 4 1 1 1 0 0 2 2 3 4 1 1 1 1 1 1 1 1 1 1 1 1 1	3663 52 52 52 52 52 52 52 52 52 53 742 0.62); F= 53 742 0.62); F= 57 57 57 57 57 57 57 57 57 57	2 54 10776 3 3 7 0 1 0 1 23 56 23 51 23 56 1 2 1 2 55 55 = 0% 1 56 7 34 895 304 892 895 3008 44% 14%	tal Weight 04 5.5. 100.0° 5.7. 0.4 5.7. 1.70 3.1. 3.83 8.8. 7.1 3.1.3. 1.67 100. tal Weight wave 3.1.3. 1.33 3.3.5. 1.4 48.4	0 3.53 (0.84, 19.37) 5 2.73 (1.65, 4.51) 0 0.04ds Ratio pt M.H., Fixed, 95%, 93% 2.82 (0.11, 65) 3.22 (0.11, 65) 3.12 (0.10, 617 3.12 (0.11, 23) 3.13 (0.11, 23, 156) 3.12 (0.11, 23) 3.48 (0.12, 13), 156 3.23 (0.11, 24) 3.53 (0.11, 24) 0.68 (0.12, 13) 4.68 (0.42, 518) 0.88 (0.12, 43) 0.58 (0.12, 44) 0% 2.20 (1.10, 4.3) 0.54 (1.37, 9.15) 1.10 (0.15, 7.7) % 3.54 (1.37, 9.15) 1.38 (1.37, 9.15)	Dot 0.1 1 10 100 Favours [hcw] Favours [control] 00dds Ratio CI M-H, Fixed, 95% CI 10 00 10 10 10 10 10 10 10 10
Total (95% C)) Total events Heterogeneth; Chi [#] Test for overall effect Strata: Medical staff – 1 Study or Subgroup Kaabia 2009 Moens 2000 Nakashima 1993 Ozavy 2003 Polish 1993 David 1995 Sermoneta-Gentel 2 Struet 1994 Total (95% C)) Total (95% C) Total (95% C) Stata: Laboratory staff Settay or Subgroup Kelerogeneth; Chi [#] Test for overall effect Strata: Laboratory staff Settay or Subgroup Total (95% C)) Total events Heterogeneth; Chi [#] Test for overall effect Total (95% C)) Total events Heterogeneth; Chi [#] Setta: Laboratory staff Setta: Laboratory	4 344 344 344 545 545 545 545 545 545 54	2736 f= 8 (P < 0.) based co HCW hts Tr 1 1 0 0 2 2 2 2 2 2 3 4 1 1 1 2 2 3 3 4 1 1 2 3 3 4 1 1 2 2 3 3 4 1 1 1 2 2 3 3 4 1 1 2 2 3 3 5 1 1 1 0 0 2 3 3 5 2 4 1 1 2 2 3 5 5 1 1 1 2 2 3 5 5 1 1 1 2 2 3 5 5 1 1 1 2 2 5 3 5 1 1 1 2 2 5 1 1 1 2 2 5 3 5 1 1 1 2 2 5 3 5 5 1 1 1 2 2 5 3 5 5 1 1 1 2 2 5 3 5 5 1 1 1 1 2 2 5 5 5 1 1 1 1 2 2 5 5 5 1 1 1 1	363 = 0.26); 00001) ontrois otal Eve 120 52 45 33 112 52 45 53 378 401 63 533 742 0.62); P ⁺ 1378 401 63 533 742 0.62); P ⁺ 1378 401 533 742 0.62); P ⁺ 1378 401 533 742 0.62; P ⁺ 1378 405 1378 407 1378 407 1378 407 1378 407 1378 407 1378 407 1378 407 1378 407 1378 407 1378 407 1378 407 1378 407 1378 407 1378 407 1378 1	2 54 10776 3 2 78* 20% 78* Control 1 0 1 23 56 1 2 1 2 1 1 3 4 19 10 3 6 10 1 3 6 10 1 3 6 10 1 3 6 10 1 3 6 3 6 3 6 3 6 3 6 3 6 3 6 3 6 3 6 3 7 3 6 3 6 3 7 3 6 3 7 3 </td <td>tal Weight 04 5.5. 100.0° 3.5. 100.0° 3.5. 100.0° 3.5. 100.0° 3.5. 100.0° 3.5. 1000 12. 1000 12. 1000 12. 1000 12. 1000 12. 100. 3.1.5. 11 48.4</td> <td>0 3.53 (0.84, 19.37) 5 2.73 [1.65, 4.51] 0 0.0dds Ratio 101 M.H., Fixed, 95%, 22.52 (0.11, 65, 73) 3/8 2.84 (1.00, 61, 72) 3/8 2.48 (1.00, 61, 72) 3/8 2.48 (1.00, 61, 72) 3/8 2.48 (1.00, 61, 72) 3/8 2.48 (1.00, 61, 72) 3/8 2.48 (1.02, 61, 72) 3/8 2.69 (1.02, 4.03) 0.58 (1.61, 74) 0.58 (1.61, 74) 0.58 (1.61, 74) 0.58 (1.61, 74) 1.04 (1.01, 72) 1.03 (1.01, 72) 1.138 (1.61, 71, 73, 41) 1.03 (1.01, 72) 1.138 (1.61, 73, 9.15) 1.138 (1.61, 73, 9.15) 1.138 (1.61, 72) 1.138 (1.61, 72) 1.138 (1.61, 72) 1.138 (1.61, 72) 1.138 (1.61, 72) 1.138 (1.61, 72) 1.138 (1.61, 72) 1.138 (1.61, 72) 1.138 (1.61, 72) 1.138 (1.61, 72) 1.138 (1.61, 72) 1.138 (1.61, 72) 1.138 (1.61, 72) 1.138 (1.61, 72) 1.138 (1.61, 72) 1.138 (1.61, 72) 1.138 (1.61, 72) <</td> <td>D Odds Ratio CI M-H, Fixed, 95% CI 00 00 00 00 00 00 00 00 00 0</td>	tal Weight 04 5.5. 100.0° 3.5. 100.0° 3.5. 100.0° 3.5. 100.0° 3.5. 100.0° 3.5. 1000 12. 1000 12. 1000 12. 1000 12. 1000 12. 100. 3.1.5. 11 48.4	0 3.53 (0.84, 19.37) 5 2.73 [1.65, 4.51] 0 0.0dds Ratio 101 M.H., Fixed, 95%, 22.52 (0.11, 65, 73) 3/8 2.84 (1.00, 61, 72) 3/8 2.48 (1.00, 61, 72) 3/8 2.48 (1.00, 61, 72) 3/8 2.48 (1.00, 61, 72) 3/8 2.48 (1.00, 61, 72) 3/8 2.48 (1.02, 61, 72) 3/8 2.69 (1.02, 4.03) 0.58 (1.61, 74) 0.58 (1.61, 74) 0.58 (1.61, 74) 0.58 (1.61, 74) 1.04 (1.01, 72) 1.03 (1.01, 72) 1.138 (1.61, 71, 73, 41) 1.03 (1.01, 72) 1.138 (1.61, 73, 9.15) 1.138 (1.61, 73, 9.15) 1.138 (1.61, 72) 1.138 (1.61, 72) 1.138 (1.61, 72) 1.138 (1.61, 72) 1.138 (1.61, 72) 1.138 (1.61, 72) 1.138 (1.61, 72) 1.138 (1.61, 72) 1.138 (1.61, 72) 1.138 (1.61, 72) 1.138 (1.61, 72) 1.138 (1.61, 72) 1.138 (1.61, 72) 1.138 (1.61, 72) 1.138 (1.61, 72) 1.138 (1.61, 72) 1.138 (1.61, 72) <	D Odds Ratio CI M-H, Fixed, 95% CI 00 00 00 00 00 00 00 00 00 0
Total (95% C)) Total events Heterogeneth; Chi [#] Test for overall effect Strata: Medical staff – 1 Study or Subgroup Kaabia 2009 Moens 2000 Nakashima 1993 Ozavy 2003 Polish 1993 David 1995 Sermoneta-Gentel 2 Struet 1994 Total (95% C)) Total (95% C) Total (95% C) Stata: Laboratory staff Settay or Subgroup Kelerogeneth; Chi [#] Test for overall effect Strata: Laboratory staff Settay or Subgroup Total (95% C)) Total events Heterogeneth; Chi [#] Test for overall effect Total (95% C)) Total events Heterogeneth; Chi [#] Setta: Laboratory staff Setta: Laboratory	4 34, 34, 34, 34, 34, 34, 34, 34, 34, 34,	2786 f = 8 (P < 0.) hassed oc HCW nts T T 1 1 2 2 3 3 4 1 4 8 (P = 0.0 3 1 1 1 2 2 3 3 4 1 1 2 2 3 3 4 1 1 2 2 3 3 4 1 1 2 2 3 3 4 1 1 2 2 3 3 4 1 1 2 2 2 3 3 4 1 1 2 2 2 3 3 4 1 1 2 2 3 3 4 1 1 2 2 2 3 3 4 1 1 2 2 2 3 3 4 1 1 2 2 2 3 3 4 1 1 2 2 2 3 3 4 1 1 2 2 2 3 3 4 1 1 2 2 2 3 3 4 1 1 2 2 2 3 3 4 1 1 2 2 2 3 3 4 1 1 2 2 2 3 3 4 1 1 2 2 2 3 3 4 1 1 2 2 2 2 3 3 4 1 1 2 2 2 3 3 4 1 1 2 2 2 3 4 1 1 1 2 2 2 3 4 1 1 1 2 2 8 4 1 1 1 2 2 8 8 4 1 1 1 2 2 8 8 8 8 8 8 8 8 8 8 8 8 8	36:3 36:2 36:2 36:2 37:0 52 52 52 52 52 52 52 52 52 52	2 54 10776 3 1° = 20% Control Control 1 0 4 2 3 56 1 2 2 19 110 3 4 1 9 1 5 5 = 0% Control 1 7 3 6 3 4 1 9 1 5 6 = 0% Control 1 9 10 1 9 2 3 4 2 0 9 1 9 2 3 4 2 0 9 1 9 2 1 9 10 1 9 10	tal Weight 04 5.2 100.05 2 04 5.2 126 1.2 126 1.2 170 3.3 130 2.3 130 2.3 131 3.1 320 3.1 331 5.7 141 48.4 94 100.0	0 3.53 (0.84, 19.37) 5 2.73 (1.65, 4.51) 0 0.04ds Ratio pt M.H., Fixed, 95%, 93% 2.82 (0.11, 65) 3.22 (0.11, 65) 3.12 (0.10, 617 3.12 (0.11, 23) 3.13 (0.11, 23, 156) 3.12 (0.11, 23) 3.48 (0.12, 13), 156 3.23 (0.11, 24) 3.53 (0.11, 24) 0.88 (0.12, 13) 4.65 (0.42, 518) 0.88 (0.12, 43) 0.58 (0.12, 44) 0% 2.20 (1.10, 4.3) 0.54 (1.37, 9.15) 1.10 (0.15, 7.7) % 3.54 (1.37, 9.15) 1.38 (1.37, 9.15)	D D D D D D D D D D D D D D
Total (95% C) Total events Heterogeneth; Chif Test for overall effect Strata: Medical staff – 1 Study or Subgroup Moens 2000 Nokasehima 1993 Ozsay 2003 Polish 1993 Bermoneta-Ortel 22 Struct 1995 Bermoneta-Ortel 22 Struct 1994 Thorburn 2001 Total (95% C) Total events Heterogeneth; Chif Test for overall effect Strata: Laboratory staf Strata: Laboratory staf Deta for Subgroup Cala (95% C) Total events Heterogeneth; Chif Test for overall effect Strata: Laboratory staf Strata: Dental staff (m Strata: Overall effect Strata: Dental staff (m	4 34, 34 34, 37 34, 39	2786 (P < 0.) (P < 0.) massed oc HCW HCW 1 1 1 0 0 2 2 3 3 2 2 3 3 2 2 3 3 1 4 1 2 8 (P = 0.0 1 1 2 2 8 4 1 1 2 2 8 (P = 0.0 1 1 1 2 2 2 8 4 1 1 2 2 8 4 1 1 2 2 8 4 1 1 2 2 8 4 1 1 1 2 8 (P = 0.0 1 1 1 2 2 2 8 4 1 1 2 2 8 4 1 1 2 2 8 4 1 1 1 2 8 4 1 1 2 2 8 4 8 4 1 1 2 2 8 4 8 4 1 1 2 2 8 4 8 4 8 4 8 4 8 4 8 4 8 4 8 4	36:3 = 0.26); 0001) whitrois the second	2 54 10776 3 17 = 20% Control 1 2 2 3 56 1 2 2 3 56 1 2 1 3 12 1 9 110 1 3 6 1 3 4 1 91 5 5 = 0% Control 1 5 5 6 0 1 1 2 3 4 1 91 5 5 = 0% Control 1 2 3 4 1 91 5 5 = 0% Control 1 2 3 4 1 91 1 91 5 6 = 0% Control 1 2 3 4 1 91 1 9	tal Weight 100.05 2 </td <td>0dds Ratio 0dds Ratio 1.45 (1.05, 4.51) 0dds Ratio 1.41, Fixed, 95% 2.62 (0.11, 65.0) 1.04 (0.06, 19.1) 1.04 (0.06, 19.1) 1.04 (0.06, 19.1) 3.4 (50) (0.12, 51.8) 1.04 (0.06, 19.1) 3.4 (50) (0.12, 51.8) 4.05 (0.12, 51.8) 1.05 (0.17, 6.3) 4.05 (0.14, 12.9) 1.228 (1.61, 10.34) 1.238 (1.61, 10.34) 1.238 (1.61, 10.34) 1.238 (1.61, 10.34) 3.54 (1.37, 51.7) % 3.54 (1.37, 61.6) 1.56 (0.46, 5.23) Odds Ratio 1.144 (0.46, 5.23)</td> <td>0 0.01 0.1 10 100 Favours [hcw] Favours [control] 0.01 0.01 0.01 0 0.04 68400 0.01 0.01 0.01 0.01 0.01 0.1 0.01</td>	0dds Ratio 0dds Ratio 1.45 (1.05, 4.51) 0dds Ratio 1.41, Fixed, 95% 2.62 (0.11, 65.0) 1.04 (0.06, 19.1) 1.04 (0.06, 19.1) 1.04 (0.06, 19.1) 3.4 (50) (0.12, 51.8) 1.04 (0.06, 19.1) 3.4 (50) (0.12, 51.8) 4.05 (0.12, 51.8) 1.05 (0.17, 6.3) 4.05 (0.14, 12.9) 1.228 (1.61, 10.34) 1.238 (1.61, 10.34) 1.238 (1.61, 10.34) 1.238 (1.61, 10.34) 3.54 (1.37, 51.7) % 3.54 (1.37, 61.6) 1.56 (0.46, 5.23) Odds Ratio 1.144 (0.46, 5.23)	0 0.01 0.1 10 100 Favours [hcw] Favours [control] 0.01 0.01 0.01 0 0.04 68400 0.01 0.01 0.01 0.01 0.01 0.1 0.01
Total (95% CI) Total avents Heterogeneith; Chi ² Test for overall effect Strata: Medical staff – j Study or Subgroup Kaabia 2009 Makashima 1993 Ozsay 2009 Nakashima 1993 Ozsay 2009 Polish 1993 Polish 1993 Polish 1993 Polish 1993 Sermoneta-Gettel 21 Strata (95% CI) Total events Heterogeneity; Chi ² Test for overall effect Strata: Laboratory staf Sermoneta-Gettel 22 Takahama 2005 Total (95% CI) Total events Heterogeneity; Chi ² Test for overall effect Strata: Data events Heterogeneity; Chi ² Test for overall effect Strata: Dental staff (m Strata: Dental staff (m Strata: Ossay 2007) De Mercata 1990	4 $34, 34, 54, 54, 54, 54, 54, 54, 54, 54, 54, 5$	2786 (P < 0.) Assed oc HCW htts Tri 0 0 2 2 3 3 4 10 2 2 2 3 3 4 11 1 1 1 1 1 1 1 1 1 1 1 1	36:5 = 0.265; 00001) Introls otal Eve 52 52 52 52 53 53 53 53 53 53 53 53 53 53 53 53 53	2 54 10776 3 10776 3 17 20% Control 1 0 1 2 2 56 2 2 56 2 2 3 56 2 2 3 56 2 2 3 56 2 2 3 56 2 3 56 1 9 11 3 4 1 9 11 3 4 1 9 11 3 4 1 9 11 3 6 2 3 56 5 5 5 5 5 5 5 5 5 5 5 5 5 5	tal Weight 0.4 5 2 0.4 5.2 100.0* 0.4 5.2 100.0* 0.4 5.2 100.0* 1.26 1. 1.26 1.26 1. 1.26 1.26 1. 1.31 1.30 23 21.5 1.31 31.1 36.7 1.32 21.5 1.1 4.4 4.4 4.4 9.4 100.0* 1. 4.4 9.4 100.0*	0 3.53 (0.84, 19.37) 2.73 [1.65, 4.51] 0.0dds Ratio 0 M.H., Fixed, 95% 2.82 (0.11, 65) 3.53 (0.84, 19.37) 3% 2.62 (1.01, 65) 3% 2.62 (1.01, 65) 3% 2.62 (0.11, 65) 3% 2.62 (1.01, 10, 10, 17) 3% 2.64 (1.01, 0.617 R) 3% 4.62 (1.38, 156) 2% 1.05 (0.17, 63) 4.62 (1.34, 156) 4.62 (1.10, 4.3) 0.645 Ratio 1.03 (0.15, 7.7) 1.03 (0.15, 7.7) 1.03 (0.15, 7.7) 3.54 [1.37, 9.15] Fa Odds Ratio 1.03 (0.15, 7.7) 1.03 (0.15, 7.7) 5.3.54 [1.37, 9.15]	0 0
Total (95% C) Total events Heterogeneth; Chi [†] Test for overall effect Strata: Medical staff – 1 Study or Subgroup Moens 2000 Nakashima 1993 Ozsay 2003 Polish 1993 Evernoneta-Oentel 22 Struck 1994 Thorburn 2001 Total (95% C) Total events Heterogeneth; Chi ⁺ Test for overall effect Strata: Laboratory staff Strata: Dantal staff (m Strata: Openation Strata 1990 Fujiyara 1992	4 34, 34, 34, 34, 34, 34, 34, 34, 34, 34,	2786 (P < 0.) 2786 (P < 0.) assed oc HCW 1 1 1 0 0 0 2 2 3 3 2 2 1 1 1 4 1 2 1 4 1 2 1 4 1 2 1 4 1 2 1 2 1 4 1 2 2 3 3 4 1 1 1 2 1 4 1 2 1 2 1 4 1 1 1 2 1 4 1 1 1 4 1 2 1 4 1 1 1 4 1 1 1 2 1 4 1 1 2 4 1 1 1 2 1 4 1 1 2 4 1 1 1 4 1 1 2 4 1 1 1 1 2 4 1 1 1 1 2 4 1 1 2 4 1 1 1 1 2 4 1 1 1 1 2 4 1 1 1 1 2 4 1 1 1 1 1 1 2 4 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	36:53 52 52 52 52 52 52 52 52 52 52	2 54 10776 3 17 = 20% Control 0 1 0 1 0 1 0 1 0 1 0 1 0 1 0 1	tal Weight 04 5. 100.0° 5. 100.0° 5. 100.0° 6. 100.0° 7. 100.0° 7. 100.0° 7. 100.0° 7. 100.0° 7. 100.0° 7. 100.0° 7. 11 48.4 9. 56.5° 9. 56.5° 9. 54.5° 1. 44.4	0 3.53 (0.84, 19.37) 5 2.73 (1.65, 4.51) 0 0.04ds Ratio 0.1 M.H., Fixed, 95% 2 2.62 (0.11, 0.5.0) 3% 2.62 (0.11, 0.5.0) 3% 2.62 (0.11, 0.5.0) 3% 2.62 (0.11, 0.5.0) 3% 1.64 (0.00, 61.8) 1.04 (0.00, 18.1) 1.04 (0.00, 18.1) 3% 4.65 (0.42, 51.8) 3% 4.65 (0.42, 51.8) 1.05 (0.17, 0.3) 0.08 (0.11, 0.3.4) 0% 2.20 (1.10, 4.3) 1.28 (0.11, 10.3.4) 1.29 (0.11, 7.3.7) 1.29 (0.11, 10.3.4) 1.29 (0.11, 7.3.7) 1.29 (0.11, 10.3.4) 1.29 (0.11, 7.3.7) 1.29 (0.14, 1.29.7) 3.54 (1.37, 9.15) Fa 0.09 (0.15, 7.7) 3.3.54 (1.37, 9.15) Fa 0.04ds Ratio 1.56 (0.46, 5.29) 1.56 (0.46, 5.29) 5.30 (0.25, 7.95) 1.56 (0.46, 5.29) 2.0.3 (0.52, 7.45)	D CI CI Favours [hcw] CI Odds Ratio CI M-H, Fixed, 95% CI CI Odds Ratio CI CI CI M-H, Fixed, 95% CI CI CI CI CI M-H, Fixed, 95% CI CI CI CI CI CI CI M-H, Fixed, 95% CI CI CI CI CI CI CI CI CI CI
Total (95% C) Total events Heterogeneth; Chi [†] Test for overall effect Strata: Medical staff – 1 Study or Subgroup Moens 2000 Neakashima 1993 Ozsay 2003 Pulos 1995 Sermoneta-Oentel 22 Struce 1994 Thorbum 2001 Total (95% C) Total events Heterogeneth; Chi ⁺ Test for overall effect Strata: Laboratory staff Study or Subgroup Heterogeneth; Chi ⁺ Test for overall effect Strata: Laboratory staff Heterogeneth; Chi ⁺ Test for overall effect Strata: Laboratory staff Heterogeneth; Chi ⁺ Test for overall effect Strata: Laboratory staff Heterogeneth; Chi ⁺ Heterogeneth; Chi ⁺ Test for overall effect Strata: Dental staff (m Study or Subgroup De Mercatol 1996 Fujiyama 1992 Puro 1995	4 $34, 34, 54, 54, 54, 54, 54, 54, 54, 54, 54, 5$	2786 P 2786 P (P < 0.) (P < 0.) (P < 0.) (P < 0.) (P < 0.) (P < 0.) 0 0 0 2 2 2 2 3 3 4 1 1 2 2 3 3 4 1 2 2 2 3 4 1 1 2 2 2 3 4 1 1 2 2 2 2 2 2 3 4 1 1 2 2 2 2 2 2 2 2 2 2 2 2 2	36:5 = 0.26); 00001) introis total Eve 52 52 52 52 52 52 52 52 52 52 52 52 52	2 54 10776 3 1 ¹ ² = 20% Control 0 1 0 4 5 2 23 56 1 2 2 3 56 1 2 1 3 12 1 9 110 5 5 5 5 5 5 5 5 5 5 5 5 5	tal Weight 04 5. 2 100.0° tal Weight 030 23. 1001 12. 1001 12. 1001 12. 1001 12. 11 48.4 100.0 11. 11 Weight 5 22.6% 5 58.5% 5 58.5% 5 58.5% 5 58.5% 5 14.45%	0dds Ratio 0dds Ratio 0dds Ratio 1.4, Fixed, 95% 2.62 (0.11, 05.0 3.24 (1.00, 61.1) 3.24 (1.00, 61.1) 3.4 (1.00, 61.1) 3.4 (1.00, 61.1) 3.4 (1.00, 61.1) 3.4 (1.00, 61.1) 3.4 (1.00, 61.1) 3.4 (1.00, 61.1) 3.4 (1.00, 61.1) 3.4 (1.00, 61.1) 3.4 (1.00, 61.1) 3.4 (1.00, 61.1) 3.4 (1.00, 61.1) 3.4 (1.00, 61.1) 3.4 (1.00, 61.1) 3.4 (1.00, 61.1) 3.4 (1.00, 61.1) 4.6 (1.00, 61.1) 5.1 (1.01, 4.3) 0.10 (1.10, 4.3) 1.29 (1.10, 4.3) 1.29 (1.11, 1.10, 4.3) 1.29 (1.11, 1.10, 4.3) 1.29 (1.11, 1.10, 4.1) 1.29 (1.11, 1.10, 4.1) 1.29 (1.11, 1.10, 4.1) 1.29 (1.10, 4.1, 2.9) 1.29 (1.10, 4.1, 2.9) 1.29 (1.10, 4.1, 2.9) 1.29 (1.10, 4.1, 2.9) 1.29 (1.10, 4.1, 2.9) 1.29 (1.10, 4.1, 2.9) 1.29 (1.10, 4.1, 2.9	D CI CI Favours [hcw] CI M-H, Fixed, 95% CI CI M-H, Fixed, 95% CI CI CI M-H, Fixed, 95% CI CI CI CI M-H, Fixed, 95% CI CI CI CI CI CI M-H, Fixed, 95% CI CI CI CI CI CI CI M-H, Fixed, 95% CI CI CI CI CI CI CI CI CI CI
Total (95% CI) Total avents Heterogeneth; Chi ² Test for overall effect Strata: Medical staff – j Study or Subgroup Kaabia 2009 Moles 2009 Natashima 1993 Ozay 2003 Polish 1993 Polish 1993 Polish 1993 Sermoneta-Gentel 21 Strue 1994 Thorbum 2001 Total (95% CI) Total events Heterogeneth; Chi ² Test for overall effect Strata: Laboratory staf Strata: Laboratory staf Strata: Laboratory staf Strata: Laboratory staf Strata: Child (95% CI) Total (95% CI) Total (95% CI) Total events Heterogeneth; Chi ² Test for overall effect Strata: Dental staff (m Strata: Dental staff (m Strata: 1995 Strata: 1995	$\begin{array}{c} 4 \\ 334 \\ = 10.05, d, \\ 10.5, d, \\ 10$	2786 17 = 8 (P (P < 0.) HCW HCW 1 1 1 0 0 0 2 2 3 14 8 (P = 0.0 3 14 8 (P = 0.0 3 14 1 2 2 2 3 1 1 1 2 2 2 3 1 1 1 2 2 2 2 3 3 1 1 2 2 2 3 3 1 1 2 2 2 3 3 1 1 2 2 2 3 3 1 1 2 2 2 3 3 1 1 2 2 2 3 3 1 1 2 2 3 3 1 1 2 2 3 3 1 1 2 2 3 3 1 1 2 2 3 3 1 1 1 2 2 3 3 1 1 2 2 3 3 1 1 1 2 2 2 3 3 1 1 2 2 2 3 3 1 1 2 2 2 3 3 1 1 2 2 2 3 3 1 2 2 2 3 3 1 2 2 2 3 3 1 2 2 2 2 2 3 1 2 2 2 2 2 2 2 2 3 1 2 2 2 2 2 2 2 2 2 2 2 2 2	36:5 36:5 36:5 36:5 37:6 38 112 120 52 52 52 52 53 38 112 120 52 53 3778 401 533 3778 401 63 533 3778 401 63 533 3778 405 533 533 63 53 63 53 63 53 63 53 63 53 63 53 63 53 63 53 63 53 63 53 63 53 63 54 64 55 55 55 55 57 57 57 57 57 57	2 54 10776 3 1776 3 17 20% Control 10 4 5 5 23 56 23 56 23 56 19 110 3 4 19 110 10 4 4 19 110 10 4 10 110 10 110 10 110 10 10 10 10 1	tal Weight 04 5. 100.0° 5. 100.0° 5. 100.0° 6. 100.0° 7. 100.0° 7. 100.0° 7. 100.0° 7. 100.0° 7. 100.0° 7. 100.0° 7. 11 48.4 9. 56.5° 9. 56.5° 9. 54.5° 1. 44.4	0dds Ratio 0dds Ratio 0dds Ratio 1.4, Fixed, 95% 2.62 (0.11, 05.0 3.24 (1.00, 61.1) 3.24 (1.00, 61.1) 3.4 (1.00, 61.1) 3.4 (1.00, 61.1) 3.4 (1.00, 61.1) 3.4 (1.00, 61.1) 3.4 (1.00, 61.1) 3.4 (1.00, 61.1) 3.4 (1.00, 61.1) 3.4 (1.00, 61.1) 3.4 (1.00, 61.1) 3.4 (1.00, 61.1) 3.4 (1.00, 61.1) 3.4 (1.00, 61.1) 3.4 (1.00, 61.1) 3.4 (1.00, 61.1) 3.4 (1.00, 61.1) 4.6 (1.00, 61.1) 5.1 (1.01, 4.3) 0.10 (1.10, 4.3) 1.29 (1.10, 4.3) 1.29 (1.11, 1.10, 4.3) 1.29 (1.11, 1.10, 4.3) 1.29 (1.11, 1.10, 4.1) 1.29 (1.11, 1.10, 4.1) 1.29 (1.11, 1.10, 4.1) 1.29 (1.10, 4.1, 2.9) 1.29 (1.10, 4.1, 2.9) 1.29 (1.10, 4.1, 2.9) 1.29 (1.10, 4.1, 2.9) 1.29 (1.10, 4.1, 2.9) 1.29 (1.10, 4.1, 2.9) 1.29 (1.10, 4.1, 2.9	D CI CI Favours [hcw] CI M-H, Fixed, 95% CI CI M-H, Fixed, 95% CI CI CI M-H, Fixed, 95% CI CI CI CI M-H, Fixed, 95% CI CI CI CI CI CI M-H, Fixed, 95% CI CI CI CI CI CI CI M-H, Fixed, 95% CI CI CI CI CI CI CI CI CI CI
Total (95% C) Total events Heterogeneth; Chi [†] Test for overall effect Strata: Medical staff – 1 Study or Subgroup Moens 2000 Nakashima 1993 Ozay 2003 Polish 1993 Evenneta-Ortel 22 Struce 1994 Thorburn 2001 Total (95% C) Total events Heterogeneth; Chi ⁺ Test for overall effect Strata: Laboratory staf Study or Subgroup Total (95% C) Total events Heterogeneth; Chi ⁺ Test for overall effect Strata: Laboratory staf Strata: Datal (95% C) Total (95% C) Total (95% C) Total (95% C) Total (95% C) Total (95% C) Total (95% C)	4 34, 34, 34, 34, 34, 34, 34, 34, 34, 34,	2786 2786 1 = 8 (P < 0.) (P <	36:5 = 0.26); 00001) httrois total Eve 52 52 52 52 52 52 52 52 52 52 52 52 52	2 54 10776 3 17 = 20% 1 0 1 0 4 23 56 1 2 1 3 4 191 55 = 0% Control 1 1 3 4 194 55 = 0% Control 1 1 3 4 194 55 = 0% Control 1 1 7 3 6 3004 822 9308 24% controls 1 is Total 9 11000 12900 12000	tal Weight 04 5. 2 100.0° tal Weight 030 23. 1001 12. 1001 12. 1001 12. 1001 12. 11 48.4 100.0 11. 11 Weight 5 22.6% 5 58.5% 5 58.5% 5 58.5% 5 58.5% 5 14.45%	0dds Ratio 0dds Ratio 0dds Ratio 1.4, Fixed, 95% 2.62 (0.11, 05.0 3.24 (1.00, 61.1) 3.24 (1.00, 61.1) 3.4 (1.00, 61.1) 3.4 (1.00, 61.1) 3.4 (1.00, 61.1) 3.4 (1.00, 61.1) 3.4 (1.00, 61.1) 3.4 (1.00, 61.1) 3.4 (1.00, 61.1) 3.4 (1.00, 61.1) 3.4 (1.00, 61.1) 3.4 (1.00, 61.1) 3.4 (1.00, 61.1) 3.4 (1.00, 61.1) 3.4 (1.00, 61.1) 3.4 (1.00, 61.1) 3.4 (1.00, 61.1) 4.6 (1.00, 61.1) 5.1 (1.01, 4.3) 0.10 (1.10, 4.3) 1.29 (1.10, 4.3) 1.29 (1.11, 1.10, 4.3) 1.29 (1.11, 1.10, 4.3) 1.29 (1.11, 1.10, 4.1) 1.29 (1.11, 1.10, 4.1) 1.29 (1.11, 1.10, 4.1) 1.29 (1.10, 4.1, 2.9) 1.29 (1.10, 4.1, 2.9) 1.29 (1.10, 4.1, 2.9) 1.29 (1.10, 4.1, 2.9) 1.29 (1.10, 4.1, 2.9) 1.29 (1.10, 4.1, 2.9) 1.29 (1.10, 4.1, 2.9	Dot 0.1 0.1 10 100 Favours [hcw] Favours [control] 00d6 Ratio CI MH, Fixed, 95% CI 10 001 0.1 10 100 Favours [hcw] Favours [control] 00 001 0.1 10 100 Favours [hcw] Favours [control] 00 0046 Ratio 00 0046 Ratio 00 0046 Ratio 00 0046 Ratio 00 0046 Ratio 00 00 00 00 00 00 00 00 00 0
Total (95% CI) Total avents Heterogeneth; Chi ² Test for overall effect Strata: Medical staff – j Study or Subgroup Kaabia 2009 Moles 2009 Natashima 1993 Ozay 2003 Polish 1993 Polish 1993 Polish 1993 Sermoneta-Gentel 21 Strue 1994 Thorbum 2001 Total (95% CI) Total events Heterogeneth; Chi ² Test for overall effect Strata: Laboratory staf Strata: Laboratory staf Strata: Laboratory staf Strata: Laboratory staf Strata: Child (95% CI) Total (95% CI) Total (95% CI) Total events Heterogeneth; Chi ² Test for overall effect Strata: Dental staff (m Strata: Dental staff (m Strata: 1995 Strata: 1995	4 $34, 34, 34, 34, 34, 34, 34, 34, 34, 34, $	$\begin{array}{c} \text{2786} \\ \text{2786} \\ \text{min} \\ m$	36:5 36:5 36:5 36:5 37:6 45:5 52 52 52 52 52 52 52 52 52 5	2 54 10776 3 17 = 20% 1 0 1 0 4 23 56 1 2 1 3 4 191 55 = 0% Control 1 1 3 4 194 55 = 0% Control 1 1 3 4 194 55 = 0% Control 1 1 7 3 6 3004 822 9308 24% controls 1 is Total 9 11000 12900 12000	tal Weight 04 5. 2 100.0° tal Weight 030 23. 1001 12. 1001 12. 1001 12. 1001 12. 11 48.4 100.0 11. 11 Weight 5 22.6% 5 58.5% 5 58.5% 5 58.5% 5 58.5% 5 14.45%	0dds Ratio 0dds Ratio 0dds Ratio 1.4, Fixed, 95% 2.62 (0.11, 05.0 3.24 (1.00, 61.1) 3.24 (1.00, 61.1) 3.4 (1.00, 61.1) 3.4 (1.00, 61.1) 3.4 (1.00, 61.1) 3.4 (1.00, 61.1) 3.4 (1.00, 61.1) 3.4 (1.00, 61.1) 3.4 (1.00, 61.1) 3.4 (1.00, 61.1) 3.4 (1.00, 61.1) 3.4 (1.00, 61.1) 3.4 (1.00, 61.1) 3.4 (1.00, 61.1) 3.4 (1.00, 61.1) 3.4 (1.00, 61.1) 3.4 (1.00, 61.1) 4.6 (1.00, 61.1) 5.1 (1.01, 4.3) 0.10 (1.10, 4.3) 1.29 (1.10, 4.3) 1.29 (1.11, 1.10, 4.3) 1.29 (1.11, 1.10, 4.3) 1.29 (1.11, 1.10, 4.1) 1.29 (1.11, 1.10, 4.1) 1.29 (1.11, 1.10, 4.1) 1.29 (1.10, 4.1, 2.9) 1.29 (1.10, 4.1, 2.9) 1.29 (1.10, 4.1, 2.9) 1.29 (1.10, 4.1, 2.9) 1.29 (1.10, 4.1, 2.9) 1.29 (1.10, 4.1, 2.9) 1.29 (1.10, 4.1, 2.9	D CI CI Favours [hcw] CI M-H, Fixed, 95% CI CI M-H, Fixed, 95% CI CI CI M-H, Fixed, 95% CI CI CI CI M-H, Fixed, 95% CI CI CI CI CI CI M-H, Fixed, 95% CI CI CI CI CI CI CI M-H, Fixed, 95% CI CI CI CI CI CI CI CI CI CI

Strata: Combining professionals at high risk for blood contacts - population-based controls

Figure 2 Forest plots of high and moderate quality studies on hepatitis C among healthcare workers. HCWs, health care workers.

 I^2 =61, see online supplementary table S3). The increased prevalence of HCV infection in HCWs was also observed in the 14 studies with high and moderate methodological quality, using population control groups and confirmatory tests (OR 1.6; 95% CI 1.03 to 2.42, no evidence of heterogeneity, figure 2).

After stratification by publication period, HCWs were found to have a statistically significant increased prevalence of HCV infection in the period 1989–2000 compared with all controls (OR 1.3; 95% CI 1.09 to 1.63). For the period 2000–2014, the pooled effect estimate was the same, but without a statistically significant increase (OR 1.3; 95% CI 0.89 to 2.02). As there are only a few current studies, it was not possible to conduct a test for time trend by subgroups (see online supplementary table S3).

The following analyses were based on high and moderate quality studies only.

Study region

Pooled analysis of studies from countries with comparably low HCV prevalence in Europe (Belgium, Denmark, France, Scotland, Sweden) and the USA showed a significantly increased prevalence of HCV infection in HCWs compared with controls (OR 2.1; 95% CI 1.31 to 3.42, figure 2). Further stratification by population-based controls could not be performed because of considerable variability between the studies ($I^2=70$). Pooled analysis of Japanese studies showed no increased HCV prevalence in HCWs (OR 1.1). Stratification of studies from the other countries by individual regions resulted in a statistically significant increased HCV prevalence in HCWs only for North Africa, the Middle East and South Asia (OR 1.9; 95% CI 1.10 to 3.15), compared to controls (see online supplementary table S3).

Gender

Six studies reported anti-HCV prevalence stratified by gender. By pooling studies using population-based controls with confirmatory tests, a significantly increased prevalence was observed only for male HCWs (women OR 1.5; 95% CI 0.45 to 5.24; men OR 3.1; 95% CI 1.21 to 7.99).

Professions

Medical staff: For medical personnel, pooled analysis of studies with confirmatory tests gave an OR of 2.7 (95% CI 1.65 to 4.51, figure 2). For medical staff excluding dentists, the OR was 2.2 (95% CI 1.30 to 3.77) for a HCV infection compared to population-based controls (see online supplementary material table S3).

Dental staff (medical and non-medical): Pooled analysis of studies with confirmatory tests gave an OR of 3.5 (95% CI 1.37 to 9.15, figure 2) for a HCV infection among dental staff compared to controls. Further stratification could not be performed because of considerable variability between the three studies.

Nursing staff: The pooled analysis of studies with confirmatory tests showed an OR of 1.7 (95% CI 0.86 to 3.31) for nursing staff compared to the population-based controls (see online supplementary table S3).

Laboratory staff: Pooled analysis of studies with confirmatory tests gave an increased OR of 2.2 (95% CI 1.10 to 4.39, figure 2) for a HCV infection in laboratory staff compared with all controls.

Professionals at high risk for blood contacts: Six sources contributed data on the following professions/working areas performing EPPs: surgeons, midwives, microbiologists, pathologists, blood bank and dialysis staff. All studies were published before 2000. The pooled analysis shows a statistically significant increased OR of 2.3 (95% CI 1.51 to 3.54) for a HCV infection

among HCWs compared with all controls and of 2.7 (95% CI 1.84 to 5.53, figure 2) compared to population-based controls.

Heterogeneity and sensitivity analysis

Heterogeneity was present when pooling all studies. Pooling the studies with high and moderate methodological quality only, reduced heterogeneity. Further stratification was performed related to performance of confirmatory tests. In addition, individual studies were then sequentially excluded from the analysis in order to verify their influence on the pooled estimate.

Publication bias

The funnel plot did not show evidence of publication bias (see online supplementary figure S3), nor did Egger's linear regression show significant evidence of funnel plot asymmetry (intercept 0.19, 90% CI 0.33 to 0.71, p=0.47).

DISCUSSION

This is the first systematic review to perform a meta-analysis on the prevalence of HCV infection among HCWs in comparison to controls. The pooled analysis of high and moderate quality studies gave a statistically significant increase in OR of 1.6 for HCV infection among HCWs compared to population-based controls. Stratified pooled analysis of studies with confirmatory tests from countries with comparable low HCV prevalence also resulted in a statistically significant increase in OR for HCWs in comparison to controls (OR 2.1). Stratification by occupational groups demonstrated an increased prevalence among medical staff (OR 2.2), laboratory staff (OR 2.2) and dental staff (medical and non-medical, OR 3.5), compared to controls. However, due to the few studies found for dental staff, further stratification by profession could not be performed. In addition, the pooled effect estimated is mainly caused by one high quality study with a wide CI.³² When the pooled analysis was stratified by nursing staff, no significant increase in OR was found. A differentiated examination of activity profile-related occupational hazards was carried out for this profession in only a few studies. This lack of differentiation may lead to underestimation of the occupational risk of infection due to exposure misclassification. This happens particularly when HCWs who are frequently exposed to blood while performing EPPs are examined in combination with less exposed HCWs in the same job category. Pooled analysis for each individual group-such as cleaning staff -was not possible as the studies were few and their methods heterogeneous in design, HCWs examined, serological testing and controls. This diversity is the main reason for the lack of consensus in the assessment of the occupational risk of HCV infection in HCWs.⁸¹⁻⁸³ Additionally, it is difficult to quantify the occupational risk given to a specific profession, such as for laboratory staff, as there is no systematic record of how exposure depends on the activity.⁸⁴ To estimate HCV prevalence in HCWs due to specific work profiles, we conducted an exemplary pooled analysis of professions that performed EPPs in accordance with the criteria of Trevisan et al.⁵⁰ The pooled analysis shows a significantly increased OR of 2.7 for these employees in comparison to the population-based controls. However, the results of this subgroup analysis are based only on studies published before 2000. The assessment of personal risk factors for a HCV infection was not performed consistently in the investigated studies, particularly in studies published earlier. Those examinations were conducted prior to the Needlestick Safety and Prevention Act (NSPA). Both in the USA and in Europe, guidelines have been issued since 2000 that aim to prevent exposure to blood, for example, from NSI.^{6 85}

The results of studies that could not be included in the quantitative analysis did not conflict with the results of the meta-analysis. Professions that performed EPPs are exposed to NSI, with a HCV transmission rate of 1.8% after an NSI according to Henderson,⁸³ Riddell and Sherrard,⁸⁶ and Baldo et al.⁸⁷ The results of an American multicentre study performed in 2006 showed that occupational exposure was greater in male HCWs.⁸⁸ The authors observed that men were three times more frequently infected than their female colleagues. In this context, bivariate analysis showed that glove use when performing invasive work was significantly associated with the female gender. According to the reviews of Kubitschke et al⁸ and Goniewicz et al,⁸⁹ NSIs were more frequent in inexperienced personnel. Current findings on the incidence of NSI in the health service show that nursing^{6 88 90} and medical personnel⁸⁸ are the most frequently affected professional group. According to Butsashvili et al^{88} the highest number of exposures to NSI is in dialysis work. The most recent research on dialvsis staff (2006-2010) concluded that there had been no decrease in the number of observed NSIs suffered by staff.⁶

Strengths and limitations

This is the first meta-analysis to examine the prevalence of HCV infection in HCWs compared to controls. However, the mostly retrospective studies included some recent studies. In addition, older studies tend to report higher anti-HCV prevalence rates than more recent studies (as confirmed by Larnev et al^{91}). As there are only a few current studies, it was not possible to draw reliable conclusions about a time trend. Most of the populationbased controls were blood donors. Individuals at risk of HCV infection in the general population were probably not included. The results of the studies that referred to reference populations must also be viewed critically. HCWs and controls may not have been tested under identical conditions. Few studies have examined how occupational hazards depend on the activity profile. This lack of differentiation may lead to underestimation of the occupational risk of infection for specific HCWs. So, the present results reveal a strong demand for further differentiated research.

Quality of serological testing

The quality of the confirmatory tests used clearly differs between individual studies. This is due to the development of better detection methods over time, the quality of the procedure or the fact that there is no fundamental difference between the antigens used in the screening and the confirmatory tests. Owing to the limitations in the sensitivity of the first anti-HCV tests (false negatives), earlier studies tended to underestimate seroprevalence. In contrast, limitations in specificity lead to false positive results. This may result in non-differential misclassification, which again is most likely to lead to decreased effect estimates.

Assessment of personal risk factors

The personal risk factors for HCV infection were not recorded consistently in the studies. The risk factors, such as use of injected drugs and injury-prone sex (men with men) were not collected in many studies, especially the earlier ones. The 1998 report of the US Center for Disease Control and Prevention (CDC) on the known risks of HCV infection identified drug use and injury-prone sex as the most common causes.¹⁵ Of the six studies that allow stratification by gender, only two examined these confounding factors, which are associated with a higher

risk of non-occupationally acquired HCV infection, especially among men. $^{32\ 36}$

CONCLUSION

This meta-analysis shows a statistically significant increase in the prevalence of HCV infection in HCWs compared to controls. Medical and laboratory personnel, and staff members who perform EPPs, are particularly affected. For other professions, no adequate calculation of a pooled estimate was possible. Prevalence of HCV infection has probably decreased since 2000, due to improved prevention. However, this needs to be investigated further. To analyse HCWs' occupational risk of infection, prospective studies are needed that focus on HCWs in terms of specific work profiles bearing in mind the importance of assessment of personal risk factors for infection. Contact with blood, for example, from NSI, is associated with a risk of infection and continues to be the major threat to the health of HCWs. Targeted prevention measures must be based on the epidemiological detection and evaluation of work-related accidents. Readily accessible reporting and treatment procedures, and the use of safe practices for working with blood, can help to minimise occupational exposure.

Collaborators Melanie Harling.

Contributors CW conceived the study protocol, performed the study selection, data extraction, quality assessment and statistical analysis, and wrote the first draft of the manuscript. CP was involved in performing data extraction, quality assessment and statistical analysis and made substantial contributions toward revising the first draft. BL performed the study selection and assessment, and made substantial contributions toward revising the first draft. AN coordinated the study, amended the study protocol, assisted in study selection and statistical analysis, and made substantial contributions toward revising the first draft. AN coordinated the study, amended the study substantial contributions toward revising the first draft.

Competing interests None declared.

Provenance and peer review Not commissioned; externally peer reviewed.

Open Access This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/ licenses/by-nc/4.0/

REFERENCES

- 1 World Health Organization. *Prevention and control of viral hepatitis infection:* framework for global action. Geneva, 2012:28.
- 2 Askarian M, Yadollahi M, Kuochak F, et al. Precautions for health care workers to avoid hepatitis B and C virus infection. Int J Occup Environ Med 2011;2:191–8.
- 3 Te HS, Jensen DM. Epidemiology of hepatitis B and C viruses: a global overview. *Clin Liver Dis* 2010;14:1–21, vii.
- 4 Deuffic-Burban S, Delarocque-Astagneau E, Abiteboul D, et al. Blood-borne viruses in health care workers: prevention and management. J Clin Virol 2011;52:4–10.
- 5 Nienhaus A, Kesavachandran C, Wendeler D, et al. Infectious diseases in healthcare workers—an analysis of the standardised data set of a German compensation board. J Occup Med Toxicol 2012;7:8.
- 6 Elseviers MM, Arias-Guillen M, Gorke A, et al. Sharps injuries amongst healthcare workers: review of incidence, transmissions and costs. J Ren Care 2014;40:150–6.
- 7 Himmelreich H, Rabenau HF, Rindermann M, et al. The management of needlestick injuries. Dtsch Arztebl Int 2013;110:61–7.
- 8 Kubitschke A, Bahr MJ, Aslan N, et al. Induction of hepatitis C virus (HCV)-specific T cells by needle stick injury in the absence of HCV-viraemia. Eur J Clin Invest 2007;37:54–64.
- 9 Sulkowski MS, Ray SC, Thomas DL. Needlestick transmission of hepatitis C. JAMA 2002;287:2406–13.
- 10 Yazdanpanah Y, De CG, Migueres B, *et al.* Risk factors for hepatitis C virus transmission to health care workers after occupational exposure: a European case-control study. *Clin Infect Dis* 2005;41:1423–30.
- 11 Wicker S, Rabenau HF, Haberl AE, et al. Blutübertragbare Infektionen und die schwangere Mitarbeiterin im Gesundheitswesen. Risiko und Präventionsmaßnahmen Blood-borne infections and the pregnant health care worker. Risks and preventive measures. *Chirurg* 2012;83:136–42.

- 12 Hofmann F, Kralj N, Beie M. Kanülenstichverletzungen im Gesundheitsdienst-Häufigkeiten, Ursachen und Präventionsstrategien Needle stick injuries in health care—frequency, causes und preventive strategies. *Gesundheitswesen* 2002;64:259–66.
- 13 Dulon M, Nienhaus A. Aktuelle Trends bei Infektionskrankheiten der Beschäftigten im Gesundheitsdienst—2008 bis 2012. In: Nienhaus A, ed. *RiRe—Risiken und Ressourcen in Gesundheitsdienst und Wohlfahrtspflege*. Heidelberg: Ecomed Medizin, 2014:27–40.
- 14 Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 2000;283:2008–12.
- 15 [No authors listed]. Public Health Service guidelines for the management of health-care worker exposures to HIV and recommendations for postexposure prophylaxis. Centers for Disease Control and Prevention. *MMWR Recomm Rep* 1998;47:1–33.
- 16 Downs SH, Black N. The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions. J Epidemiol Community Health 1998;52:377–84.
- 17 Loney PL, Chambers LW, Bennett KJ, et al. Critical appraisal of the health research literature: prevalence or incidence of a health problem. Chronic Dis Can 1998;19:170–6.
- 18 Higgins JPT, Green S, eds. *Cochran handbook for systematic reviews of interventions* 4.2.6. Chichester, UK: John Wiley & Sons, 2006.
- 19 Slim K, Nini E, Forestier D, et al. Methodological index for non-randomized studies (minors): development and validation of a new instrument. ANZ J Surg 2003;73:712–16.
- 20 Vandenbroucke JP, von Elm E, Altman DG, et al. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration. PLoS Med 2007;4:e297.
- 21 Hahne SJ, Veldhuijzen IK, Wiessing L, *et al*. Infection with hepatitis B and C virus in Europe: a systematic review of prevalence and cost-effectiveness of screening. *BMC Infect Dis* 2013;13:181.
- 22 Mohd Hanafiah K, Groeger J, Flaxman AD, et al. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. *Hepatology* 2013;57:1333–42.
- 23 Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315:629–34.
- 24 Puro V, Petrosillo N, Ippolito G, et al. Occupational hepatitis C virus infection in Italian health care workers. Italian Study Group on Occupational Risk of Bloodborne Infections. Am J Public Health 1995;85:1272–5.
- 25 Maillard MF, Poynard T, Dubreuil P, et al. Prevalence of serum anti-hepatitis C virus antibodies and risk factors of contamination in the personnel of a hospital in the Paris region. A prospective survey. Gastroenterol Clin Biol 1996;20:1053–7.
- 26 Cooper BW, Krusell A, Tilton RC, et al. Seroprevalence of antibodies to hepatitis C virus in high-risk hospital personnel. Infect Control Hosp Epidemiol 1992;13:82–5.
- 27 Ahmetagic S, Muminhodzic K, Cickusic E, *et al.* Hepatitis C infection in risk groups. *Bosn J Basic Med Sci* 2006;6:13–17.
- 28 Daw MA, Elkaber MA, Drah AM, *et al.* Prevalence of hepatitis C virus antibodies among different populations of relative and attributable risk. *Saudi Med J* 2002;23:1356–60.
- 29 Mihaly I, Telegdy L, Ibranyi E, et al. Prevalence, genotype distribution and outcome of hepatitis C infections among the employees of the Hungarian Central Hospital for infectious diseases. J Hosp Infect 2001;49:239–44.
- 30 Gershon RR, Sherman M, Mitchell C, et al. Prevalence and risk factors for bloodborne exposure and infection in correctional healthcare workers. Infect Control Hosp Epidemiol 2007;28:24–30.
- 31 Ozsoy MF, Oncul O, Cavuslu S, *et al*. Seroprevalences of hepatitis B and C among health care workers in Turkey. *J Viral Hepat* 2003;10:150–6.
- 32 Klein RS, Freeman K, Taylor PE, *et al*. Occupational risk for hepatitis C virus infection among New York City dentists. *Lancet* 1991;338:1539–42.
- 33 Sermoneta-Gertel S, Donchin M, Adler R, et al. Hepatitis c virus infection in employees of a large university hospital in Israel. Infect Control Hosp Epidemiol 2001;22:754–61.
- 34 Thomas DL, Gruninger SE, Siew C, et al. Occupational risk of hepatitis C infections among general dentists and oral surgeons in North America. Am J Med 1996;100:41–5.
- 35 Struve J, Aronsson B, Frenning B, *et al*. Prevalence of antibodies against hepatitis C virus infection among health care workers in Stockholm. *Scand J Gastroenterol* 1994;29:360–2.
- 36 Braczkowska B, Kowalskan M, Zejda JE, et al. Prevalence and basic determinants of hepatitis C antibodies in medical students in Katowice, Poland. Przegl Lek 2006;63:539–42.
- 37 Fisker N, Mygind LH, Krarup HB, et al. Blood borne viral infections among Danish health care workers--frequent blood exposure but low prevalence of infection. Eur J Epidemiol 2004;19:61–7.
- 38 Ciorlia LA, Zanetta DM. Hepatitis C in health care professionals: prevalence and association with risk factors. *Rev Saude Publica* 2007;41:229–35.
- 39 Moens G, Vranckx R, de Greef L, *et al.* Prevalence of hepatitis C antibodies in a large sample of Belgian healthcare workers. *Infect Control Hosp Epidemiol* 2000;21:209–12.

Review

- 40 Thorburn D, Dundas D, McCruden EA, et al. A study of hepatitis C prevalence in healthcare workers in the West of Scotland. Gut 2001;48:116–20.
- 41 Djeriri K, Fontana L, Laurichesse H, et al. Seroprevalence of markers of viral hepatitis A, B and C in hospital personnel at the Clermont-Ferrand University Hospital Center. Presse Med 1996;25:145–50.
- 42 Villate JI, Corral J, Aguirre C, et al. Hepatitis C virus antibodies in hospital personnel. *Med Clin (Barc)* 1993;100:766–9.
- 43 Montella M, Crispo A, Grimaldi M, et al. An assessment of hepatitis C virus infection among health-care workers of the National Cancer Institute of Naples, Southern Italy. Eur J Public Health 2005;15:467–9.
- 44 Kaabia N, Ben JE, Hannachi N, *et al*. Prevalence of hepatitis C virus among health care workers in central Tunisia. *Med Mal Infect* 2009;39:66–7.
- 45 Irani-Hakime N, Aoun J, Khoury S, et al. Seroprevalence of hepatitis C infection among health care personnel in Beirut, Lebanon. Am J Infect Control 2001;29:20–3.
- 46 Campello C, Majori S, Poli A, et al. Prevalence of HCV antibodies in health-care workers from northern Italy. *Infection* 1992;20:224–6.
- 47 Polish LB, Tong MJ, Co RL, et al. Risk factors for hepatitis C virus infection among health care personnel in a community hospital. Am J Infect Control 1993;21:196–200.
- 48 Perez Trallero E, Cilla G, Alcorta M, et al. Low risk of acquiring the hepatitis C virus for the health personnel. *Med Clin (Barc)* 1992;99:609–11.
- 49 Takahama AJ, Tatsch F, Tannus G, et al. Hepatitis C: incidence and knowledge among Brazilian dentists. Community Dent Health 2005;22:184–7.
- 50 Trevisan A, Bicciato F, Fanelli G, et al. Risk of hepatitis C virus infection in a population exposed to biological materials. Am J Ind Med 1999;35:532–5.
- 51 Weber C, Coller-Schaub D, Fried R, et al. Low prevalence of hepatitis C virus antibody among Swiss dental health care workers. J Hepatol 2001;34:963–4.
- 52 Shapiro CN, Tokars JI, Chamberland ME. Use of the hepatitis-B vaccine and infection with hepatitis B and C among orthopaedic surgeons. The American Academy of Orthopaedic Surgeons Serosurvey Study Committee. J Bone Joint Surg Am 1996;78:1791–800.
- 53 Goetz AM, Ndimbie OK, Wagener MM, *et al.* Prevalence of hepatitis C infection in health care workers affiliated with a liver transplant center. *Transplantation* 1995;59:990–4.
- 54 Ahmed F, Irving WL, Anwar M, et al. Prevalence and risk factors for hepatitis C virus infection in Kech District, Balochistan, Pakistan: most infections remain unexplained. A cross-sectional study. *Epidemiol Infect* 2012;140:716–23.
- 55 Fischer LR, Tope DH, Conboy KS, *et al.* Screening for hepatitis C virus in a health maintenance organization. *Arch Intern Med* 2000;160:1665–73.
- 56 De Mercato R, Guarnaccia D, Ciannella G, *et al.* Hepatitis C virus among health care workers. *Minerva Med* 1996;87:501–4.
- 57 Olubuyide IO, Ola SO, Aliyu B, *et al.* Prevalence and epidemiological characteristics of hepatitis B and C infections among doctors and dentists in Nigeria. *East Afr Med J* 1997;74:357–61.
- 58 al-Sohaibani MO, al-Sheikh EH, al-Ballal SJ, et al. Occupational risk of hepatitis B and C infections in Saudi medical staff. J Hosp Infect 1995;31:143–7.
- 59 Soni PN, Tait DR, Kenoyer DG, et al. Hepatitis C virus antibodies among risk groups in a South African area endemic for hepatitis B virus. J Med Virol 1993;40:65–8.
- 60 Oguchi H, Miyasaka M, Tokunaga S, *et al*. Hepatitis virus infection (HBV and HCV) in eleven Japanese hemodialysis units. *Clin Nephrol* 1992;38:36–43.
- 61 Nakashima K, Kashiwagi S, Hayashi J, et al. Low prevalence of hepatitis C virus infection among hospital staff and acupuncturists in Kyushu, Japan. J Infect 1993;26:17–25.
- 62 Fujiyama S, Kawano S, Sato S, et al. Prevalence of hepatitis C virus antibodies in hemodialysis patients and dialysis staff. *Hepatogastroenterology* 1992;39:161–5.
- 63 Germanaud J, Barthez JP, Causse X. The occupational risk of hepatitis C infection among hospital employees. *Am J Public Health* 1994;84:122.
- 64 Jindal N, Jindal M, Jilani N, *et al*. Seroprevalence of hepatitis C virus (HCV) in health care workers of a tertiary care centre in New Delhi. *Indian J Med Res* 2006;123:179–80.

- 65 Kuo MY, Hahn LJ, Hong CY, et al. Low prevalence of hepatitis C virus infection among dentists in Taiwan. J Med Virol 1993;40:10–13.
- 66 Zaaijer HL, Appelman P, Frijstein G. Hepatitis C virus infection among transmissionprone medical personnel. *Eur J Clin Microbiol Infect Dis* 2012;31:1473–7.
- 67 Zuckerman J, Clewley G, Griffiths P, *et al.* Prevalence of hepatitis C antibodies in clinical health-care workers. *Lancet* 1994;343:1618–20.
- 68 Jochen AB. Occupationally acquired hepatitis C virus infection. *Lancet* 1992;339:304.
- 69 el Gohary A, Hassan A, Nooman Z, et al. High prevalence of hepatitis C virus among urban and rural population groups in Egypt. Acta Trop 1995;59:155–61.
- 70 Polywka S, Laufs R. Hepatitis C virus antibodies among different groups at risk and patients with suspected non-A, non-B hepatitis. *Infection* 1991;19:81–4.
- 71 Hindy AM, Abdelhaleem ES, Aly RH. Hepatitis B and C viruses among Egyptian dentists. *Egypt Dent J* 1995;41:1217–26.
- 72 Khan S, Attaullah S, Ayaz S, *et al.* Molecular epidemiology of HCV among health care workers of khyber pakhtunkhwa. *Virol J* 2011;8:105.
- 73 Mijakoski D, Karadzinska-Bislimovska J, Stikova E, et al. Occupational sharp injuries and biological markers of hepatitis B and hepatitis C viral infection in nurses. *Macedonian J Med Sci* 2012;4:417–27.
- 74 Kondili LA, Ulqinaku D, Hajdini M, et al. Hepatitis B virus infection in health care workers in Albania: a country still highly endemic for HBV infection. *Infection* 2007;35:94–7.
- 75 Libanore M, Bicocchi R, Ghinelli F, *et al.* Prevalence of antibodies to hepatitis C virus in Italian health care workers. *Infection* 1992;20:50.
- 76 Mujeeb SA, Khatri Y, Khanani R. Frequency of parenteral exposure and seroprevalence of HBV, HCV, and HIV among operation room personnel. J Hosp Infect 1998;38:133–7.
- 77 Sarkari B, Eilami O, Khosravani A, et al. High prevalence of hepatitis C infection among high risk groups in Kohgiloyeh and Boyerahmad Province, Southwest Iran. Arch Iran Med 2012;15:271–4.
- 78 Vardas E, Ross MH, Sharp G, et al. Viral hepatitis in South African healthcare workers at increased risk of occupational exposure to blood-borne viruses. J Hosp Infect 2002;50:6–12.
- 79 Shoaei P, Lotfi N, Hassannejad R, *et al*. Seroprevalence of hepatitis C infection among laboratory health care workers in Isfahan, Iran. *Int J Prev Med* 2012;3:S146–9.
- 80 De Luca M, Ascione A, Vacca C, *et al.* Are health-care workers really at risk of HCV infection? *Lancet* 1992;339:1364–5.
- Sepkowitz KA. Occupationally acquired infections in health care workers. Part II. Ann Intern Med 1996;125:917–28.
- 82 Lanphear BP. Transmission and control of bloodborne viral hepatitis in health care workers. Occup Med (Lond) 1997;12:717–30.
- 83 Henderson DK. Managing occupational risks for hepatitis C transmission in the health care setting. *Clin Microbiol Rev* 2003;16:546–68.
- 84 Singh K. Laboratory-acquired infections. *Clin Infect Dis* 2009;49:142-7.
- 85 Phillips EK, Conaway MR, Jagger JC. Percutaneous injuries before and after the Needlestick Safety and Prevention Act. *N Engl J Med* 2012;366:670–1.
- 86 Riddell LA, Sherrard J. Blood-borne virus infection: the occupational risks. Int J STD AIDS 2000;11:632–9.
- 87 Baldo V, Baldovin T, Trivello R, *et al*. Epidemiology of HCV infection. *Curr Pharm Des* 2008;14:1646–54.
- 88 Butsashvili M, Kamkamidze G, Kajaia M, et al. Occupational exposure to body fluids among health care workers in Georgia. Occup Med (Lond) 2012;62:620–6.
- 89 Goniewicz M, Wloszczak-Szubzda A, Niemcewicz M, et al. Injuries caused by sharp instruments among healthcare workers--international and Polish perspectives. Ann Agric Environ Med 2012;19:523–7.
- 90 Shah SM, Bonauto D, Silverstein B, et al. Workers' compensation claims for needlestick injuries among healthcare workers in Washington State, 1996–2000. Infect Control Hosp Epidemiol 2005;26:775–81.
- 91 Larney S, Kopinski H, Beckwith CG, *et al.* Incidence and prevalence of hepatitis C in prisons and other closed settings: results of a systematic review and meta-analysis. *Hepatology* 2013;58:1215–24.